



Universidad Peruana Cayetano Heredia

Independent auditor's report on ninety-four (94) Research Projects funded with U.S. Federal Funds under contracts and subcontracts signed between Universidad Peruana Cayetano Heredia with the following funding institutions: (i) National Institute of Health - NIH; (ii) Center of Disease Control - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program, and (v) several U.S. universities, for the period of twelve (12) months from January 1, 2023 to December 31, 2023

Universidad Peruana Cayetano Heredia

Research Projects funded with U.S. Federal Funds under contracts and subcontracts signed between Universidad Peruana Cayetano Heredia with the following funding institutions: (i) National Institute of Health - NIH; (ii) Center of Disease Control - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program, and (v) several U.S. universities

Independent auditors' report

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

Contents

I. Remittance letter and summary

- (a) Background
- (b) Objectives of audit
- (c) Scope and audit procedures
- (d) Audit results

II. Consolidated statement of expenses

- (a) Independent auditor's report
- (b) Consolidated statement of income
- (c) Individual statements of income
- (d) Notes to the consolidated statement of expenses

III. Evaluation of the internal control system of the Projects

- (a) Independent auditor's report
- (b) Additional notes to the evaluation of the internal control system of the Projects

IV. Evaluation of compliance with the terms of the funding contracts and subcontracts, and the applicable laws and regulations

- (a) Independent auditor's report
- (b) Additional notes to the report on compliance with the terms of the financing contracts and subcontracts, applicable laws and regulations

V. Opportunities for improvement and recommendations

Key:

- US\$ = U.S. dollar
- S/ = Peruvian Sol

Remittance letter and summary

To the members of the Board of Universidad Peruana Cayetano Heredia

This report contains the results of our audit of ninety-four (94) research projects funded with united States Federal Funds under contracts and subcontracts signed between Universidad Peruana Cayetano Heredia with the following funding institutions: (i) National Institute of Health - NIH; (ii) Center for Control of Health - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program, and (v) several U.S. universities, for the period of twelve (12) months from January 1, 2023 to December 31, 2023.

(a) Background

Universidad Peruana Cayetano Heredia

Universidad Peruana Cayetano Heredia (hereinafter, the University) was created under Supreme Decree N° 018 enacted by the Peruvian Government on September 22, 1961. It is an academic and autonomous non-governmental nonprofit institution with legal status under private law, of indefinite duration. Also, the University is authorized to receive bequests and donations for the fulfillment and fulfillment of its purposes. Its purpose is to provide higher education, promote and disseminate scientific research in all fields and professionally prepare students, as well as to promote university extension work; also, its fundamental purpose is to turn people into agents of scientific, technological, social and environmental change based on lifelong education. It provides training to professionals with social and ethical commitment, who provide integral solutions with a solid research base and respect for diversity and the environment, at the undergraduate, graduate, post graduate specialization and continuing education.

The legal address of the University is at Av. Honorio Delgado N° 430 Urbanización Ingeniería, district of San Martin de Porres, Lima, Peru.

The University is governed by Peruvian law, specifically by the New University Law 30220 and its supplemental regulations, standards statutes and directives.

Funding Research Projects

Funding for implementing the Research Projects is provided under contracts with the Universidad Peruana Cayetano Heredia to obtain U.S. federal funds by means of and directly from the following funding institutions: (i) National Institute of Health- NIH; (ii) Centers For Disease Control And Prevention; (iii) Navsup Fleet Logistics Support Center Sigonella and (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by

Remittance letter and summary (continued)

the Department of Defense HIV/AIDS Prevention Program. The funding provided by the National Institute of Health - NIH, is delivered: directly (direct contracts) between the University and the National Institute of Health - NIH; and indirectly (subcontracts), in which the National Institute of Health - NIH, finances universities in the United States of America and those institutions, in turn, subcontract the research services provided by the University.

I. **Projects that are managed under direct contracts**

The following projects are presented below:

1. **National Institutes Of Health - NIH**

- Project 1: Addressing hypertension and diabetes through community-engaged systems in Puno, Perú (Andes study)
Budget executed US\$ 740,573
- Project 2: Program for advanced research capacities for AIDS in Perú (Paracas) harnessing implementation science
Budget executed US\$ 229,604
- Project 3: Perú infectious diseases epidemiology research training consortium
Budget executed US\$393,905
- Project 4: Improving diagnostic and management tools for neurocysticercosis (Perú - JHU TMRC Program)
Budget executed US\$ 222,004
- Project 5: Combined albendazole and praziquantel in subarachnoid ncc, ccc, lead application
Budget executed US\$ 47,905
- Project 6: Understanding immune modulation in taenia solium neurocysticercosis by using a novel postoncosphere in vitro model
Budget executed US\$ 188,805
- Project 7: Patient - Centered intervention to prevent tuberculosis among children < 5 years old
Budget executed US\$ 72,385
- Project 8: A mobile phone short message service intervention to increase retention in HIV (Weltel Perú)
Budget executed US\$ 138,692
- Project 9: The effect of strongyloides stercoralis on HTLV-1 disease progression
Budget executed US\$ 46,905

Remittance letter and summary (continued)

- Project 10: Using burden of treatment as a clinical indicator of barriers to multimorbidity management in Peru: A mixed methods A Mixed Approach
Budget executed US\$ 58,765
- Project 11: 1/2 - Regional geohealth hub centered in Perú
Budget executed US\$ 246,276
- Project 12: Planning an MD-MSc combined degree program focused on translational research to build the next generation of Physician-Scientist in Perú
Budget executed US\$ 9,698
- Project 13: Genomic epidemiology of campylobacter in poultry to enable the effective control of human campylobacteriosis in a middle-income country
Budget executed US\$ 134,804
- Project 14: Equinococosis Quística Hepática: Evaluación preclínica de un nuevo enfoque tratamiento percutáneo
Budget executed US\$ 5
- Project 15: Alternative therapeutic approaches for the control of brain inflammation secondary to antihelminthic therapy in neurocysticercosis using a novel experimental pig model
Budget executed US\$ 135,251
- Project 16: Training in infectious diseases in Perú - time for implementation research
Budget executed US\$ 450,670
- Project 17: A non-inferiority randomized single blind controlled trial comparing one and two dose regimens of oxfendazole
Budget executed US\$ 24,761
- Project 18: Ensayo clínico controlado, aleatorizado, multicéntrico, de regímenes de dosis única y múltiple de oxfendazole
Budget executed US\$ 16,691

2. Centers For Disease Control And Prevention

- Project 19: Project of febrile illness surveillance in the andean and amazon countries (Pisaac)
Budget executed US\$ 1,024,738
- Project 20: Improving national knowledge and awareness of fungal infections in Perú
Budget executed US\$ 201,899

Remittance letter and summary (continued)

3. Navsup Fleet Logistics Support Center Sigonella

- Project 21: Cooperasalud: technical support for the consolidation of hiv prevention and control in the Peruvian Armed Forces
Budget executed US\$ 281,838

4. PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program

- Project 22: Cooperasalud II: Technical Assistance To Strengthen Post-Pandemic Hiv Prevention And Control Capacities In The Peruvian Armed Forces
Budget executed US\$ 25,381

II. Projects managed under subcontracts signed with:

Major projects involved are as follows:

1. Children's Hospital Los Angeles

- Project 23: Gut microbial and metabolic mediators of rotavirus vaccine response
Budget executed US\$ 72,512

2. Duke University

- Project 24: Improving response to Malaria outbreaks in Amazon-basin countries
Budget executed US\$ 157,779

3. Emory University

- Project 25: Training - 2/2 Regional geohealth hub centered in Peru-US
Budget executed US\$ 98,049

4. Kephera Diagnostics, LLC

- Project 26: Rapid point-of-care assay for diagnosis of Neurocysticercosis in seizure patients
Budget executed US\$ 15,380

5. La Jolla Institute For Immunology

- Project 27: Proteome-wide characterization of t cell epitopes from mycobacterium tuberculosis in vaccination and active infection
Budget executed US\$ 187,716

Remittance letter and summary (continued)

- Project 28: Análisis longitudinal de firmas inmunitarias (LMS) de células T específicas de M. tuberculosis
Budget executed US\$ 53,846

6. Oregon Health & Science University

- Project 29: Development and validation of an agent-based model to promote evidence-based control of taenia solium cysticercosis
Budget executed US\$ 364,365
- Project 30: Implementation of ring strategy for community engaged control of neurocysticercosis
Budget executed US\$ 232,931
- Project 31: Urine screening for early detection of subarachnoid neurocysticercosis
Budget executed US\$ 541,007

7. Research Triangle Institute International

- Project 32: Next-generation sequencing diagnostics to identify etiologies of acute undifferentiated fever in the Peruvian Amazon
Budget executed US\$ 5,483

8. Rutgers The State University of New Jersey

- Project 33: Fend for tuberculosis
Budget executed US\$ 410,384

9. ST Jude Childrens Research Hospital

- Project 34: Historia natural del SARS-CoV-2 en comparación con el virus de la influenza A
Budget executed US\$ 137

10. The Administrators Of The Tulane Educational Fund (DBA Tulane University)

- Project 35: Enabling Infectious Disease Research Capacity In The Peruvian Amazon
Budget executed US\$ 10,163

Remittance letter and summary (continued)

11. The Board Of Trustees Of The Leland Stanford Juner University

- Project 36: How land use change transforms the landscape of vector-borne disease
Budget executed US\$ 108,681

12. The Childrens Hospital Corporation D/B/A Boston CH

- Project 37: HIV risk and psychosocial health among transgender women in Perú
Budget executed US\$ 29,101

13. The Florida International University Board of Trus

- Project 38: Acceptability, feasibility, and preliminary impact of a web-based, HIV prevention toolkit with Cisge
Budget executed US\$ 68,169

14. The John Hopkins University

- Project 39: Using the mycobacterium tuberculosis genome to predict tuberculosis pathology
Budget executed US\$ 235,358
- Project 40: Predictors of cardiomyopathy progression in a chagas disease cohort in Bolivia
Budget executed US\$ 27,716
- Project 41: Infectious diseases training program in Bolivia: south - south training with Perú
Budget executed US\$ 113,834
- Project 42: Novel nanoparticulate diagnostics for Cerebral toxoplasmosis and Chagas in HIV patients living in Latinoamerica
Budget executed US\$ 59,543
- Project 43: Research training in chronic, non-communicable respiratory diseases in Perú
Budget executed US\$ 44,308
- Project 44: Investigating platelets in the innate immune response to tuberculosis
Budget executed US\$ 39,822

15. The Ohio State University

- Project 45: Tuberculosis research project UPCH-OSU
Budget executed US\$ 78,743

Remittance letter and summary (continued)

16. The Rector and Visitors of the University of Virginia

- Project 46: Enabling infectious disease research capacity in the Peruvian Amazon
Budget executed US\$ 3,936
- Project 47: Genomic Epidemiology of Campylobacter to Improve Disease Control in Low- and Middle-Income Countries
Budget executed US\$ 18,414

17. The Regents of the University of California

- Project 48: HIV prevention and care for peruvian MSM and transgender women
Budget executed US\$ 144
- Project 49: Integrating smartphone photography for Trachoma, smartphone visual acuity assessment, and mobile autorefraction to enhance community-based public health monitoring
Budget executed US\$ 78,711
- Project 50: South American Program In Hiv Prevention Research (Saphir)
Budget executed US\$ 19,608

18. The Regents Of The University Of California, San Francisco

- Project 51: University of California global health institute program for fellows and scholars
Budget executed US\$ 13,532

19. The Research Foundation For Suny, University AT-AL

- Project 52: Aplicación de nuevos biomarcadores para medir los impactos en la salud del cambio antropogénico en la Amazonia
Budget executed US\$ 4,889

20. The University Of California San Diego

- Project 53: Peruvian/Brazilian Amazon center of excellence in Malaria (transmission dynamics of residual Malaria in the Amazon)
Budget executed US\$ 578

21. The University Of North Carolina At Chapel Hill

- Project 54: Long-term mental health symptoms and psychological rehabilitation among Peruvian COVID - 19 survivors
Budget executed US\$ 47,861

Remittance letter and summary (continued)

- Project 55: An Integrated Approach To Understand And Diagnose Congenital Chagas Disease
Budget executed US\$ 7,266

22. The University of Texas Hilth Science Center at San Antonio

- Project 56: Multidisciplinary Training Program on Neuropsychiatry and behavioral disorders in First Nations (NEUFIN)
Budget executed US\$ 80,127
- Project 57: Isolation and identification of CXCR4 and CXCR7 agonists from traditional phytopharmaceuticals as potential novel drugs for mental disorders
Budget executed US\$ 41,898

23. Tufts University

- Project 58: Colonización del intestino con patógenos con resistencia antimicrobian
Budget executed US\$ 370

24. Universidad de Alabama

- Project 59: Prevalence and incidence of neonatal HSV (Herpes Simplex) in pre-term infants
Budget executed US\$ 6,741
- Project 60: A prospective study of Acute Flaccid Myelitis (AFM) to define natural
Budget executed US\$ 51,933
- Project 61: Conocimientos, actitudes y exposición frente al virus hepatitis A en estudiantes de medicina de una universidad privada de Lima, Perú
Budget executed US\$ 1,323

25. Universidad de Arizona

- Project 62: Cómo la pandemia de la COVID -19 afectó la vida y el trabajo de los agentes comunitarios de salud
Budget executed US\$ 65
- Project 63: Efectos COVID -19 en adolescentes de la región Amazónica de Loreto
Budget executed US\$ 10,861

Remittance letter and summary (continued)

26. Universidad de California

- Project 64: Conocimientos, prácticas y actitudes hacia la salud bucal infantil
Budget executed US\$ 1,071

27. Universidad de Carolina del Norte

- Project 65: CCASANET: Improving the diagnosis of HIV-associated neurocognitive disorder (HAND) in Latin America: A multimodal approach to HAND in Perú
Budget executed US\$ 43,675

28. Universidad de Duke

- Project 66: Cerrar la brecha entre la identificación y el tratamiento de las anomalías cervicales en Lima
Budget executed US\$ 62,272

29. Universidad de Harvard

- Project 67: Evaluación de urgencias, emergencias y atención neuroquirúrgica esencial en el Perú
Budget executed US\$ 2,565

30. Universidad de Texas Medical Branch - Galveston

- Project 68: Markers of triclabendazole resistant fascioliasis the highlands of Perú
Budget executed US\$ 95,390
- Project 69: One-health approach to study human Fasciola Hepatica transmission and inform strategic control
Budget executed US\$ 249,878

31. Universidad de Vanderbilt

- Project 70: Prevention Through Vaccination Training (Prevent) Program
Budget executed US\$ 54,906

32. University At Albany - State University Of New York

- Project 71: Impacto de El niño sobre el mercurio ambiental and exposición humana
Budget executed US\$ 17,139

Remittance letter and summary (continued)

- Project 72: Administración de medicamentos en masa focal para la eliminación de la Malaria Vivax (Flame)
Budget executed US\$ 280,667

33. University Of Pennsylvania

- Project 73: An immune system for the city: a new paradigm for control of urban disease vectors
Budget executed US\$ 232,441
- Project 74: Spatially responsive mass vaccination strategies for urban rabies
Budget executed US\$ 194,157

34. University of Southern California

- Project 75: Syphilis immunology and biology to improve clinical management and vaccine design
Budget executed US\$ 75,556
- Project 76: Clinical trial comparing the effectiveness of cefixime versus penicillin G for treatment of early SY
Budget executed US\$ 96,748
- Project 77: Deep VZN - Discovery & Exploration of emerging pathogens – viral zoono
Budget executed US\$ 7,778
- Project 78: Evaluating susceptibility of treponema pallidum to Novel antibiotics in clinical samples
Budget executed US\$ 5,697

35. University of Washington

- Project 79: Enhancing global health security
Budget executed US\$ 439,526
- Project 80: D43 Chronic Non-communicable CVDS and comorbidities in Perú
Budget executed US\$ 92,558
- Project 81: Ictus: Interdisciplinary cerebrovascular diseases training program in South America
Budget executed US\$ 40,285

Remittance letter and summary (continued)

- Project 82: Population assessment of Alzheimer's and related dementias in rural northern Perú
Budget executed US\$ 140,629

36. Vanderbilt University Medical Center

- Project 83: CCASANET 2021-2026, Caribbean, Central and South America Network
Budget executed US\$ 122,025
- Project 84: CCASANET 2020-2022, Caribbean, Central and South America Network
Budget executed US\$ 2,808
- Project 85: Statistical methods for correlated outcome and covariate errors in studies of HIV/AIDS
Budget executed US\$ 11,479

37. Yale University

- Project 86: Nih-Receptores Huerfanos
Budget executed US\$ 18,875
- Project 87: Transmission dynamics of residual malaria in the amazon: defining a roadmap to malaria elimination
Budget executed US\$ 124,970
- Project 88: Immunology of asymptomatic malaria and the effects of immunity on plasmodium transmission
Budget executed US\$ 47,417
- Project 89: Spatiotemporal adaptation of anopheles darling in diverse ecological settings
Budget executed US\$ 46,017
- Project 90: Translational research development for endemic infectious diseases of Amazonia
Budget executed US\$ 16
- Project 91: El comportamiento alimentario con azúcares del vector de la Malaria Nyssorhynchus Darlingi y el desarrollo de cebos de azúcares tóxicos atractivos y eficaces (ATSB) para aumentar el éxito de la intervención en el Perú
Budget executed US\$ 8,050

Remittance letter and summary (continued)

- Project 92: La infección por plasmodium disminuye los títulos de anticuerpos de COVID-19 preexistentes y compromete la inmunidad en comunidades con alto riesgo de Malaria en la Amazonía Peruana
Budget executed US\$ 15,009
- Project 93: Core B Data Management
Budget executed US\$ 21,936
- Project 94: Ampliando la caja de herramientas para la prevención de sarcopenia y osteoporosis en peruanos que envejecen con VIH: Un estudio de validación
Budget executed US\$ 7,527

(b) Objectives of audit

The objectives of the audit of the expenses incurred in the Research Projects funded with U.S. federal funds for the period of twelve (12) months from January 1, 2023 to December 31, 2023, were as follows:

- Express an opinion as to whether the consolidated statement of expenses of the ninety-four (94) research projects present fairly, in all material respects, the costs incurred during the period of twelve (12) months from January 1, 2023 to December 31, 2023, in accordance with the terms of the contracts and subcontracts, as well as GAAP or other comprehensive basis of accounting.
- Evaluate the structure of the internal control system implemented by the University, related to the Research Projects, to obtain a sufficient understanding of the design of control policies and procedures, and whether those policies and procedures have been implemented; as well as, to assess control risk and identify significant deficiencies, including material weaknesses.

(c) Scope and audit procedures

Scope

The scope of our audit work consists of performing audit procedures on all expense transactions incurred for the period of twelve (12) months from January 1, 2023 to December 31, 2023 of the ninety-four (94) Research Projects funded by U.S. federal funds.

As part of an audit and determination of the existence of an adequate control environment, we have reviewed the following documents:

- Contracts signed between Universidad Peruana Cayetano Heredia and the National Institute of Health - NIH.
- Contracts signed between Universidad Peruana Cayetano Heredia and: (i) Centers for Disease Control and Prevention; (ii) Navsup Fleet Logistics Support Center Sigonella; y (iii) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program.

Remittance letter and summary (continued)

- Subcontracts signed by Universidad Peruana Cayetano Heredia and other U.S. universities, which were funded by the National Institute of Health - NIH as well as subcontracts comprising the services rendered by the University to effect the related research work.
- Decentralized system of Information and Monitoring on Research (SIDISI, the Spanish acronym).
- Organizational flowchart.
- Description of accounting system.
- Directives containing policies and procedures for procurement and contracting implementing by the University.

Procedures

Our audit was conducted on the consolidated statement of cash flows, including an evaluation of the internal control structure, and compliance with the terms of the financing contracts and subcontracts and applicable laws and regulations as follows:

- **Consolidated statement of expenses**

Our review of the ninety-four (94) statements of expenditures (individual statements of expenditures) for each project included the amounts budgeted, the expenditures reported and compliance with the procedures established in the contracts and funding subcontracts.

The review of the adequate documentation supporting the expenses incurred by the audited Projects, with original documentation supporting the expenses.

The review of the procedures for purchases, procurement of goods, bids and quotations.

A review of the procedures for the hiring of payroll personnel and their social benefits.

A review of the procedures of services rendered by third parties, contracts, technical reports, certificates of satisfaction with the service based on the nature of the service.

Our opinion on the consolidated statement of expenses considers AICPA Statement on Auditing Standards (SAS) No. 62 (AU 623). The audit evaluated the actions taken for the execution of the Projects and the achievements obtained to determine whether specific costs incurred are allowable, allocable and reasonable under the terms of the subcontracts and the applicable cost principles; identifying areas where fraud and illegal acts have occurred, or could have occurred as a result of inadequate internal controls

Remittance letter and summary (continued)

In addition to the above, we perform the following procedures:

1. We performed tests on the University's accounting books and auxiliary records to verify whether the costs incurred were properly recorded.
 2. We performed tests on the University's accounting books and auxiliary records to verify whether the costs incurred were properly recorded.
 3. We test purchasing procedures to determine whether sound business practices have been applied, including competition, reasonable prices, and adequate controls over quality and quantity received.
 4. We performed tests on whether travel and transportation charges are properly documented and approved.
 5. We performed tests on the existence of the goods purchased by the entity and whether they were used for the purposes established in the terms of the financing contracts and subcontracts, as well as the control procedures implemented to adequately safeguard them.
 6. We tested whether the costs incurred during the year are related to the University's Projects Work Plan for the twelve (12) month period from January 1, 2023 to December 31, 2023.
- **Evaluation of the structure of the internal control system relating to Projects**

We reviewed and evaluated the structure of the University's internal control system in order to understand the design of the relevant control policies and procedures, and whether they were put in place; by performing the following procedures:

 1. We obtained a sufficient understanding of internal control to plan the audit and determine the nature, timing and extent of the audit tests to be performed.
 2. We assessed inherent and control risk, and determine detection risk to prevent or detect material weaknesses.
 3. We summarized the risk assessments for each assertion in the working papers, considering the following classifications: (a) types of transactions and events, and (b) presentation and disclosure.
 4. We evaluated the control environment, the adequacy of the accounting system and control procedures. We emphasized the policies and procedures relevant to the University's ability to record, process, summarize and report financial information consistent with the assertions contained in the consolidated statement of expenses.

Remittance letter and summary (continued)

Our evaluation included, but was not limited to, control systems to:

- Ensure that charges to financing contracts and subcontracts are correct and properly documented.
- Manage cash on hand and in bank accounts.
- procure goods and services.
- Ensure compliance with the terms of contracts and subcontracts, applicable laws and regulations that collectively have a material impact on the consolidated statement of expenses.

- **Evaluation of compliance with the terms of contracts and subcontracts for financing, applicable laws and regulations.**

During the planning and execution stage of compliance testing, we took the following into account:

1. We identified the terms of contracts and subcontracts, applicable laws and regulations; and determined which, if not complied with, could have a direct and significant effect on the consolidated statement of income, as follows:
 - a) We listed the Project's uniform and specific clauses contained in contracts and subcontracts which, in the aggregate, if not complied with, may have a direct and significant effect on the consolidated statement of expenses.
 - b) We evaluated the inherent and control risk of the occurrence of a significant noncompliance for each compliance requirement listed in the previous point.
 - c) We determined the nature, timing and extent of audit procedures and steps to perform tests to determine whether there are errors, fraud, illegal acts, that provide reasonable assurance of detecting instances of intentional or unintentional non-compliance with the terms of contracts and subcontracts, applicable laws and regulations that could have a material effect on the consolidated statement of income, based on the risk assessment described in the preceding paragraph.
2. Determine whether payments have been made in accordance with the terms of contracts and subcontracts, applicable laws and regulations.
3. We determined whether the funds were expended for authorized purposes, in accordance with the applicable terms of the financing contracts and subcontracts.
4. We determine whether the goods and services purchased were used for the purposes set forth in the terms of the financing contracts and subcontracts; otherwise, the cost of such goods should be questioned.

Remittance letter and summary (continued)

- **Other audit responsibilities**

1. We held meetings at the beginning and end of the audit with the responsible officials of the University.
2. We established quality control procedures to ensure that sufficient competent evidence was obtained from inspection, observation, interviews, and confirmations to provide a reasonable basis for our opinion on the consolidated statement of expenditure under audit. Those procedures ensure that:
 - The audit report and the documents supporting the working papers are reviewed by a partner not involved in the audit.
 - All monetary amounts and quantities involving calculations have been duly verified and referenced; and
 - All statements of facts, numbers, conclusions and monetary amounts are referenced to the working papers.
3. We obtained the Management Representation Letter signed by the University Administration.

(d) **Audit results**

- **Consolidated statement of expenses**

In our opinion, the consolidated statement of expenses comprising the ninety-four (94) research projects funded by Federal Funds of the United States of America, under the contracts and subcontracts signed between the Universidad Peruana Cayetano Heredia with the following funding institutions: (i) National Institute of Health - NIH; (ii) Centro de Control de Enfermedades - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program and (v) several U.S. universities, for the period of twelve (12) months from January 1, 2023 to December 31, 2023, present fairly the costs incurred, in accordance with the terms of the funding contracts and subcontracts signed and in conformity with the basis of accounting described in Note 2 of the Notes to the consolidated statement of expenses.

- **Evaluation of the structure of the internal control system relating to Projects**

In planning and performing our audit of the consolidated statement of expenses comprising ninety-four (94) research projects financed by Federal Funds from the United States of America, through contracts and subcontracts signed between Universidad Peruana Cayetano Heredia and the following funding entities: (i) National Institute of Health - NIH; (ii) Centro de Control de Enfermedades - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program and (v) several U.S. universities, for the period of twelve (12) months from January 1, 2023 to December 31, 2023, we considered the University's

Remittance letter and summary (continued)

internal control over financial reporting (internal control) as a basis for designing our auditing procedures for the purpose of expressing an opinion on the consolidated statement of expenditures, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control; accordingly, we express no such opinion. As a result of our examination, we found no weaknesses in the structure of the University's internal control system that merit mention as part of this report.

- **Assessment of the University's compliance with the terms of funding contracts and subcontracts, applicable laws and regulations**

The results of our compliance testing indicate that for the ninety-four (94) research projects funded by U.S. Federal Funds, under the contracts and subcontracts signed between Universidad Peruana Cayetano Heredia and the following entities: (i) National Institute of Health - NIH; (ii) Centro de Control de Enfermedades - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program and (v) several U.S. universities, for the period of twelve (12) months from January 1, 2023 to December 31, 2023, the University has complied with the terms of the signed funding contracts and subcontracts, and the applicable laws and regulations.

Countersigned by:

Luis Acosta Peche & Asociados S. Civil de R. L.

Luis R. Acosta Peche

(Partner)

Peruvian Certified Public Accountant

Registration No 14042

Lima, Peru

August 29, 2024

Independent auditor's report on the consolidated statement of expenses of Projects

To the members of the Board of Universidad Peruana Cayetano Heredia

Opinion

1. We have audited the accompanying consolidated statement of expenses comprising ninety-four (94) Research Projects (hereinafter the Projects) implemented by Universidad Peruana Cayetano Heredia (a nonprofit educational institution), which are funded with U.S. Federal Funds under the funding contracts and subcontracts signed between Universidad Peruana Cayetano Heredia and the following funding institutions: (i) National Institute of Health - NIH; (ii) Centro de Control de Enfermedades - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program and (v) several U.S. universities, for the period of twelve (12) months from January 1, 2023 to December 31, 2023.

In our opinion, the accompanying consolidated statement of expenses referred to above, present fairly, in all material respects, the expenses reported as incurred by the ninety-four (94) Research Projects, for the period of twelve (12) months from January 1, 2023 to December 31, 2023 and in accordance with the basis of accounting described in Note 2 to the Notes to the consolidated statement of expense. The Projects have complied, in all material respects, with the terms of the contracts and subcontracts signed between Universidad Peruana Cayetano Heredia and the National Institute of Health - NIH; (ii) Centro de Control de Enfermedades - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program; and (v) several U.S. universities; these are required by the U.S. federal entity and the National Institute of Health (NIH) based on Circular OMB A-133, from January 1, 2023 to December 31, 2023.

Basis for opinion

2. We have conducted our audit in accordance with the U.S. Generally Accepted Government Auditing Standards approved for their application in Peru by the Board of Deans of Institutes of Peruvian Certified Public Accountants. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the consolidated statement of expenses section of our report.

We are independent of Universidad Peruana Cayetano Heredia under the Code of Professional Ethics approved by the Board of Deans of Institutes of Peruvian Certified Public Accountants, and we have fulfilled our responsibilities under those requirements.

Independent auditor's report on the consolidated statement of expenses of Projects (continued)

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.

Responsibility of the Board of Universidad Peruana Cayetano Heredia for the consolidated statement of expenses relating to the Projects

3. The Board (Consejo Directivo) of Universidad Peruana Cayetano Heredia is responsible for the preparation and fair presentation of the consolidated statement of expenses of the ninety-four (94) Research Projects in accordance with the basis of accounting described in Note 2 to the notes to the consolidated statement of expenses, and the internal control that the Board determines is necessary to enable the preparation of financial statements that are free from material misstatements, whether due to fraud or error.

Auditor's responsibility for the audit of the consolidated statement of expenses

4. We conducted our audit of the ninety-four (94) Research Projects in accordance with the Generally Accepted Government Auditing Standards (GAGAS), of the United States of America, the U.S. Compliance Supplement of the Office of Management and Budget (OMB) - Circular A 133 and the International Auditing Standards (IAS). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated statement of expenses is free from material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated statement of expenses. An audit also includes assessing the accounting principles used and significant estimates made by the University, as well as evaluating the overall presentation of the consolidated statement of expenditures. We believe that our audit provides a reasonable basis for our opinion.

We do not have a program of quality control reviews by any outside organization, as required by Chapter 5. Paragraphs 5.60 and 5.67 of the Generally Accepted Government Auditing Standards of the United States of America, since such a program is not offered by any professional organization in Peru. We believe that the effects of this departure from U.S. Generally Accepted Government Auditing Standards are not material because the documentation of our work performed is subject to quality control reviews by partners and managers not involved with the audits performed and our Firm is subject, every two years, to an extensive quality control review by partners and managers of other Russell Bedford International member firms.

Responsibility for establishing an internal control structure

5. General Administration (Dirección General de Administración) of Universidad Peruana Cayetano Heredia is responsible for establishing and maintaining an effective internal control system. In planning and performing our audit, we considered the internal controls that could have a significant effect on the realization of the ninety-four (94) Projects' expenses to design the appropriate procedures in the performance of our audit to be in a position to express an opinion on the reasonableness of internal control in accordance with

Independent auditor's report on the consolidated statement of expenses of Projects (continued)

OMB Circular A-133. In our opinion based on our review of internal control, we did not identify any significant deficiencies in accordance with the requirements of OMB Circular A-133; for the period January 1, 2023 to December 31, 2023.

Emphasis of a matter

6. The accounting transactions of the Research Projects are recorded in U.S. dollars, which is the currency of origin; however, for purposes of preparing the statements of expenses of each of the Research Projects, these are presented in U.S. dollars and Peruvian soles only for reference purposes.

Other matters of interest

7. Due to the fact that the ninety-four (94) research projects have different annual budget periods, it is not possible to make a comparison between the approved budgets and their execution; therefore, the executed expenses are presented as indicated in the Terms of Reference for the period from January 1, 2023 to December 31, 2023.

Countersigned by:

Luis Acosta Peche & Asociados S. Civil de R. L.

Luis R. Acosta Peche

(Partner)

Peruvian Certified Public Accountant

Registration No 14042

Lima, Peru

August 29, 2024

Universidad Peruana Cayetano Heredia

Consolidated statement of expenses of ninety-four (94) Research Projects funded by U.S. Federal Funds, under contracts and subcontracts signed by Universidad Peruana Cayetano Heredia and funding institutions

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Notes | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------|-------------------|-----------------|
| <u>Direct costs</u> | | | |
| Employee benefits | 3.1 | 4,932,989 | 18,478,502 |
| Training | | 733,835 | 2,754,276 |
| Travel | | 404,055 | 1,512,929 |
| Consulting | | 460,078 | 1,718,286 |
| Equipment and/or supplies | 3.2 | 1,227,407 | 4,607,923 |
| Lab and patient care services | | 311,680 | 1,160,299 |
| Contractual expenses | | 1,007,305 | 3,755,567 |
| Others | | 987,475 | 3,695,706 |
| Total direct costs | | 10,064,824 | 37,683,488 |
| Indirect costs | | 529,082 | 1,971,855 |
| Total indirect costs incurred | | 10,593,906 | 39,655,343 |

The accompanying Notes to the consolidated statement of expenses are an integral part of this statement.

Universidad Peruana Cayetano Heredia

Consolidated statement of expenses of ninety-four (94) Research Projects funded by U.S. Federal Funds, under contracts and subcontracts signed by Universidad Peruana Cayetano Heredia and funding institutions

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Research Projects | Employee benefits | Training | Travel | Consulting | Equipment and/or supplies | Lab and patient care services | Contractual expenses | Others | Indirect costs | Total | Total |
|-------------------|-------------------|----------|--------|------------|---------------------------|-------------------------------|----------------------|--------|----------------|-----------|-----------|
| | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | S/ |
| Project 1 | 80,923 | 0 | 1,762 | 4,377 | 25,646 | 1,110 | 603,013 | 16,125 | 7,617 | 740,573 | 2,765,844 |
| Project 2 | 76,761 | 79,810 | 9,618 | 11,085 | 0 | 0 | 32,566 | 10,560 | 9,204 | 229,604 | 857,445 |
| Project 3 | 100,608 | 145,461 | 23,760 | 3,542 | 75,966 | 6,118 | 1,100 | 30,131 | 7,219 | 393,905 | 1,475,279 |
| Project 4 | 68,154 | 825 | 193 | 18,000 | 94,369 | 2,597 | 0 | 30,695 | 7,171 | 222,004 | 844,685 |
| Project 5 | 21,656 | 0 | 0 | 9,177 | 0 | 0 | 0 | 9,674 | 7,398 | 47,905 | 183,903 |
| Project 6 | 96,299 | 2,540 | 19,565 | 28,000 | 27,236 | 0 | 0 | 2,527 | 12,638 | 188,805 | 703,242 |
| Project 7 | 58,268 | 0 | 0 | 0 | 0 | 0 | 0 | 3,270 | 10,847 | 72,385 | 271,612 |
| Project 8 | 112,712 | 2,500 | 0 | 3,068 | 0 | 664 | 0 | 9,628 | 10,120 | 138,692 | 519,248 |
| Project 9 | 26,216 | 0 | 0 | 0 | 10,923 | 7,339 | 0 | 2,390 | 37 | 46,905 | 176,158 |
| Project 10 | 19,908 | 0 | 681 | 2,772 | 3,348 | 0 | 0 | 27,363 | 4,693 | 58,765 | 218,525 |
| Project 11 | 131,807 | 0 | 120 | 0 | 30,252 | 0 | 73,988 | 4,101 | 6,008 | 246,276 | 919,348 |
| Project 12 | 9,661 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 35 | 9,698 | 36,706 |
| Project 13 | 106,448 | 615 | 4,494 | 0 | 15,370 | 0 | 0 | 264 | 7,613 | 134,804 | 504,697 |
| Project 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 20 |
| Project 15 | 74,806 | 689 | 6,361 | 0 | 8,814 | 4,863 | 0 | 30,772 | 8,946 | 135,251 | 503,198 |
| Project 16 | 98,265 | 156,562 | 41,894 | 1,421 | 36,185 | 5,305 | 53,550 | 37,717 | 19,771 | 450,670 | 1,687,282 |
| Project 17 | 20,804 | 0 | 3,866 | 0 | 0 | 0 | 0 | 79 | 12 | 24,761 | 93,852 |
| Project 18 | 16,604 | 0 | 0 | 0 | 0 | 0 | 0 | 52 | 35 | 16,691 | 63,086 |
| Project 19 | 306,048 | 23,582 | 3,342 | 25,464 | 294,579 | 48,212 | 239,338 | 33,502 | 50,671 | 1,024,738 | 3,823,564 |
| Project 20 | 126,322 | 488 | 8,446 | 15,476 | 25,257 | 0 | 0 | 17,924 | 7,986 | 201,899 | 754,412 |
| Project 21 | 111,128 | 0 | 10,515 | 69,166 | 62,918 | 63 | 0 | 27,921 | 127 | 281,838 | 1,056,919 |
| Project 22 | 15,106 | 0 | 0 | 8,506 | 0 | 0 | 0 | 1,734 | 35 | 25,381 | 95,560 |
| Project 23 | 37,727 | 0 | 0 | 696 | 8,236 | 4,227 | 0 | 13,057 | 8,569 | 72,512 | 269,123 |

Universidad Peruana Cayetano Heredia

Consolidated statement of expenses of ninety-four (94) Research Projects funded by U.S. Federal Funds, under contracts and subcontracts signed by Universidad Peruana Cayetano Heredia and funding institutions

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Research Projects | Employee benefits | Training | Travel | Consulting | Equipment and/or supplies | Lab and patient care services | Contractual expenses | Others | Indirect costs | Total | Total |
|-------------------|-------------------|----------|--------|------------|---------------------------|-------------------------------|----------------------|--------|----------------|---------|-----------|
| | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | S/ |
| Project 24 | 78,525 | 47 | 35,857 | 0 | 471 | 0 | 0 | 36,140 | 6,739 | 157,779 | 592,688 |
| Project 25 | 20,950 | 44,561 | 10,608 | 0 | 6,846 | 0 | 0 | 11,458 | 3,626 | 98,049 | 365,972 |
| Project 26 | 10,221 | 0 | 2,000 | 1,654 | 0 | 1,505 | 0 | 0 | 0 | 15,380 | 58,148 |
| Project 27 | 119,018 | 0 | 0 | 0 | 9,743 | 17,952 | 0 | 30,412 | 10,591 | 187,716 | 700,031 |
| Project 28 | 46,164 | 0 | 0 | 0 | 157 | 2,100 | 0 | 4,575 | 850 | 53,846 | 202,511 |
| Project 29 | 160,449 | 0 | 40,419 | 0 | 53,593 | 7,826 | 0 | 79,812 | 22,266 | 364,365 | 1,369,371 |
| Project 30 | 122,849 | 1,074 | 6,854 | 0 | 29,745 | 4,596 | 0 | 55,814 | 11,999 | 232,931 | 874,681 |
| Project 31 | 319,890 | 7,640 | 29,197 | 0 | 28,627 | 38,323 | 0 | 83,693 | 33,637 | 541,007 | 2,019,896 |
| Project 32 | 4,253 | 0 | 0 | 0 | 1,110 | 0 | 0 | 120 | 0 | 5,483 | 20,600 |
| Project 33 | 242,839 | 1,726 | 540 | 0 | 57,810 | 48,206 | 0 | 36,461 | 22,802 | 410,384 | 1,545,642 |
| Project 34 | 137 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 137 | 507 |
| Project 35 | 10,163 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10,163 | 38,483 |
| Project 36 | 34,463 | 0 | 15,672 | 3,323 | 28,794 | 1,534 | 0 | 16,859 | 8,036 | 108,681 | 403,155 |
| Project 37 | 18,792 | 0 | 0 | 0 | 7,548 | 0 | 0 | 779 | 1,982 | 29,101 | 107,852 |
| Project 38 | 38,291 | 0 | 0 | 0 | 11,516 | 2,152 | 0 | 11,663 | 4,547 | 68,169 | 254,306 |
| Project 39 | 133,532 | 5,000 | 0 | 30,000 | 35,445 | 6,377 | 0 | 10,030 | 14,974 | 235,358 | 882,527 |
| Project 40 | 16,331 | 0 | 0 | 0 | 7,321 | 0 | 0 | 1,157 | 2,907 | 27,716 | 103,024 |
| Project 41 | 34,304 | 48,083 | 8,386 | 0 | 400 | 2,079 | 0 | 13,459 | 7,123 | 113,834 | 426,962 |
| Project 42 | 44,439 | 0 | 188 | 93 | 5,637 | 10 | 0 | 3,837 | 5,339 | 59,543 | 224,184 |
| Project 43 | 19,214 | 10,618 | 11,751 | 0 | 0 | 0 | 0 | 532 | 2,193 | 44,308 | 165,524 |
| Project 44 | 19,785 | 0 | 0 | 0 | 5,920 | 13,152 | 0 | 428 | 537 | 39,822 | 146,716 |
| Project 45 | 0 | 47,839 | 367 | 27,628 | 0 | 98 | 0 | 2,811 | 0 | 78,743 | 296,749 |
| Project 46 | 3,548 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 388 | 3,936 | 15,033 |
| Project 47 | 18,212 | 0 | 202 | 0 | 0 | 0 | 0 | 0 | 0 | 18,414 | 69,206 |
| Project 48 | 140 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 144 | 544 |
| Project 49 | 52,215 | 0 | 1,670 | 2,293 | 1,682 | 5,769 | 0 | 11,385 | 3,697 | 78,711 | 293,042 |

Universidad Peruana Cayetano Heredia

Consolidated statement of expenses of ninety-four (94) Research Projects funded by U.S. Federal Funds, under contracts and subcontracts signed by Universidad Peruana Cayetano Heredia and funding institutions

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Research Projects | Employee benefits | Training | Travel | Consulting | Equipment and/or supplies | Lab and patient care services | Contractual expenses | Others | Indirect costs | Total | Total |
|-------------------|-------------------|----------|--------|------------|---------------------------|-------------------------------|----------------------|--------|----------------|---------|-----------|
| | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | S/ |
| Project 50 | 14,608 | 0 | 0 | 5,000 | 0 | 0 | 0 | 0 | 0 | 19,608 | 72,311 |
| Project 51 | 4,579 | 5,250 | 0 | 3,300 | 0 | 0 | 0 | 1 | 402 | 13,532 | 51,223 |
| Project 52 | 4,819 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70 | 4,889 | 18,496 |
| Project 53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 578 | 0 | 578 | 2,158 |
| Project 54 | 1,173 | 38,330 | 0 | 745 | 749 | 195 | 0 | 2,860 | 3,809 | 47,861 | 177,507 |
| Project 55 | 2,841 | 0 | 0 | 0 | 4,425 | 0 | 0 | 0 | 0 | 7,266 | 27,250 |
| Project 56 | 23,464 | 43,568 | 7,252 | 0 | 0 | 0 | 0 | 1,788 | 4,055 | 80,127 | 299,805 |
| Project 57 | 21,600 | 0 | 9,764 | 4,500 | 164 | 4,019 | 0 | 1,413 | 438 | 41,898 | 157,692 |
| Project 58 | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 348 | 370 | 1,412 |
| Project 59 | 521 | 0 | 0 | 0 | 0 | 4,000 | 0 | 2,200 | 20 | 6,741 | 25,517 |
| Project 60 | 35,041 | 0 | 0 | 252 | 1,527 | 1,814 | 0 | 7,531 | 5,768 | 51,933 | 194,681 |
| Project 61 | 0 | 0 | 0 | 0 | 0 | 1,312 | 0 | 0 | 11 | 1,323 | 4,912 |
| Project 62 | 65 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 65 | 250 |
| Project 63 | 2,537 | 0 | 5,934 | 1,331 | 137 | 21 | 0 | 866 | 35 | 10,861 | 40,511 |
| Project 64 | 111 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 960 | 1,071 | 4,028 |
| Project 65 | 30,988 | 0 | 0 | 0 | 3,142 | 4,708 | 0 | 3,398 | 1,439 | 43,675 | 163,468 |
| Project 66 | 18,830 | 7,800 | 339 | 23,080 | 1,380 | 334 | 0 | 1,055 | 9,454 | 62,272 | 236,557 |
| Project 67 | 0 | 0 | 0 | 0 | 0 | 2,000 | 0 | 565 | 0 | 2,565 | 9,454 |
| Project 68 | 58,028 | 0 | 2,120 | 16,500 | 7,652 | 0 | 0 | 2,606 | 8,484 | 95,390 | 355,929 |
| Project 69 | 180,768 | 306 | 6,139 | 0 | 36,411 | 1,071 | 0 | 10,625 | 14,558 | 249,878 | 938,109 |
| Project 70 | 26,504 | 19,240 | 3,977 | 0 | 0 | 0 | 0 | 3,594 | 1,591 | 54,906 | 207,003 |
| Project 71 | 6,766 | 0 | 33 | 0 | 0 | 0 | 0 | 8,394 | 1,946 | 17,139 | 64,177 |
| Project 72 | 100,620 | 0 | 6,392 | 71,945 | 48,597 | 0 | 0 | 39,545 | 13,568 | 280,667 | 1,048,712 |
| Project 73 | 130,300 | 0 | 0 | 35,341 | 11,912 | 0 | 0 | 41,942 | 12,946 | 232,441 | 868,789 |
| Project 74 | 156,594 | 0 | 5,210 | 0 | 1,685 | 0 | 0 | 19,468 | 11,200 | 194,157 | 727,351 |
| Project 75 | 58,377 | 0 | 0 | 0 | 3,111 | 636 | 3,750 | 1,148 | 8,534 | 75,556 | 283,377 |

Universidad Peruana Cayetano Heredia

Consolidated statement of expenses of ninety-four (94) Research Projects funded by U.S. Federal Funds, under contracts and subcontracts signed by Universidad Peruana Cayetano Heredia and funding institutions

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Research Projects | Employee benefits | Training | Travel | Consulting | Equipment and/or supplies | Lab and patient care services | Contractual expenses | Others | Indirect costs | Total | Total |
|----------------------|----------------------|----------|---------|------------|---------------------------------|--|-------------------------|---------|-------------------|------------|------------|
| | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | US\$ | S/ |
| Project 76 | 49,130 | 0 | 360 | 6,168 | 17,846 | 10,000 | 0 | 5,302 | 7,942 | 96,748 | 360,489 |
| Project 77 | 2,097 | 0 | 0 | 0 | 0 | 0 | 0 | 42 | 5,639 | 7,778 | 29,006 |
| Project 78 | 3,433 | 0 | 0 | 0 | 1,694 | 0 | 0 | 570 | 0 | 5,697 | 21,474 |
| Project 79 | 385,482 | 362 | 22,818 | 0 | 145 | 0 | 0 | 5,563 | 25,156 | 439,526 | 1,644,260 |
| Project 80 | 45,440 | 39,030 | 774 | 0 | 0 | 0 | 0 | 1,983 | 5,331 | 92,558 | 346,343 |
| Project 81 | 17,350 | 0 | 0 | 0 | 17,662 | 0 | 0 | 3,154 | 2,119 | 40,285 | 152,681 |
| Project 82 | 35,827 | 0 | 1,274 | 2,000 | 6,350 | 30,550 | 0 | 64,051 | 577 | 140,629 | 522,145 |
| Project 83 | 45,207 | 0 | 7,060 | 24,175 | 19,174 | 14,245 | 0 | 4,958 | 7,206 | 122,025 | 456,035 |
| Project 84 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,808 | 2,808 | 10,298 |
| Project 85 | 10,957 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 522 | 11,479 | 43,345 |
| Project 86 | 13,597 | 0 | 0 | 0 | 2,776 | 0 | 0 | 935 | 1,567 | 18,875 | 70,077 |
| Project 87 | 71,770 | 0 | 10,892 | 0 | 19,678 | 0 | 0 | 13,518 | 9,112 | 124,970 | 469,345 |
| Project 88 | 41,272 | 0 | 2,630 | 0 | 267 | 0 | 0 | 424 | 2,824 | 47,417 | 178,078 |
| Project 89 | 30,395 | 0 | 6,131 | 0 | 3,761 | 0 | 0 | 3,261 | 2,469 | 46,017 | 172,704 |
| Project 90 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 16 | 61 |
| Project 91 | 533 | 0 | 1,058 | 0 | 273 | 0 | 0 | 2,076 | 4,110 | 8,050 | 30,213 |
| Project 92 | 2,820 | 0 | 2,625 | 0 | 3,003 | 67 | 0 | 6,494 | 0 | 15,009 | 57,058 |
| Project 93 | 13,568 | 289 | 2,945 | 0 | 2,422 | 0 | 0 | 1,654 | 1,058 | 21,936 | 82,255 |
| Project 94 | 0 | 0 | 0 | 0 | 0 | 4,531 | 0 | 2,996 | 0 | 7,527 | 27,735 |
| | 4,932,989 | 733,835 | 404,055 | 460,078 | 1,227,407 | 311,680 | 1,007,305 | 987,475 | 529,082 | 10,593,906 | 39,655,343 |

The accompanying Notes to the consolidated statement of expenses are an integral part of this statement.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 1: Addressing hypertension and diabetes through community-engaged systems
in Puno, Perú (Andes study)

Funded with U.S. Federal Funds under direct contract signed between National
Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 80,923 | 301,891 |
| Training | 0 | 0 |
| Travel | 1,762 | 6,515 |
| Consulting | 4,377 | 16,402 |
| Equipment and/or supplies | 25,646 | 96,161 |
| Lab and patient care services | 1,110 | 4,200 |
| Contractual expenses | 603,013 | 2,251,240 |
| Others | 16,125 | 60,884 |
| Total direct costs | 732,956 | 2,737,293 |
| Indirect costs | 7,617 | 28,551 |
| Total indirect costs incurred | 740,573 | 2,765,844 |

Researcher: Stella Maria Hartinger Peña

Project performance Term: September 2020 to January 2027

General objective of Project:

The objective of this research is to design and evaluate the effectiveness of a multi-component strategy for the diagnosis and treatment of hypertension (HBP) and type 2 diabetes (T2D). ANDES' multicomponent strategy is made up of 1) health campaigns with events that offer AHT/T2D diagnosis in the community and 2) follow-up led by community social actors to improve adherence to treatment.

Universidad Peruana Cayetano Heredia

Individuales statement of expenses

Project 2: Program for advanced research capacities for AIDS in Perú (Paracas)
harnessing implementation science
Funded with U.S. Federal Funds under direct contract signed between National
Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 76,761 | 285,746 |
| Training | 79,810 | 299,471 |
| Travel | 9,618 | 35,239 |
| Consulting | 11,085 | 41,119 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 32,566 | 121,556 |
| Others | 10,560 | 39,531 |
| Total direct costs | 220,400 | 822,662 |
| Indirect costs | 9,204 | 34,783 |
| Total indirect costs incurred | 229,604 | 857,445 |

Researcher: Elsa Violeta González Lagos

Project performance Term: June 2020 to December 2024

General objective of Project:

Paracas will reinforce implementation science mentor-led research training at the doctoral level for outstanding young and mid-career health researchers; this will allow them to design and test effective interventions adapted to the health context. This program should build the competent and passionate HIV scientific workforce in Peru that is needed to achieve an AIDS-free generation.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 3: Perú infectious diseases epidemiology research training consortium
 Funded with U.S. Federal Funds under direct contract signed between National
 Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 100,608 | 375,097 |
| Training | 145,461 | 546,430 |
| Travel | 23,760 | 87,920 |
| Consulting | 3,542 | 13,175 |
| Equipment and/or supplies | 75,966 | 285,770 |
| Lab and patient care services | 6,118 | 22,939 |
| Contractual expenses | 1,100 | 4,234 |
| Others | 30,131 | 112,432 |
| Total direct costs | 386,686 | 1,447,997 |
| Indirect costs | 7,219 | 27,282 |
| Total indirect costs incurred | 393,905 | 1,475,279 |

Researcher: Andrés Guillermo Lescano Guevara

Project performance Term: April 2015 to December 2024

General objective of Project:

The concurrent flu pandemic has highlighted the gaps in knowledge and response capacity of emerging infectious diseases; the objective of the consortium, among others, is to contribute to building sustainable research capacity in Peru, to have PhD graduates to study the key epidemiological and ecological aspects of pandemic and seasonal influenza; an additional purpose is to provide training to students.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 4: Improving diagnostic and management tools for neurocysticercosis (Perú - JHU TMRC Program)

Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 68,154 | 259,066 |
| Training | 825 | 3,111 |
| Travel | 193 | 745 |
| Consulting | 18,000 | 69,642 |
| Equipment and/or supplies | 94,369 | 359,307 |
| Lab and patient care services | 2,597 | 10,000 |
| Contractual expenses | 0 | 0 |
| Others | 30,695 | 116,675 |
| Total direct costs | 214,833 | 818,546 |
| Indirect costs | 7,171 | 26,139 |
| Total indirect costs incurred | 222,004 | 844,685 |

Researcher: Héctor Hugo García Lescano

Project performance Term: April 2017 to March 2023

General objective of Project:

This TMRC (Tropical Medicine Research Centers) program presented by UPCH in collaboration with the Johns Hopkins University School of Public Health (SPHJH) articulates 3 research projects and three operational units to provide a fully functional research network and leverages our research network in Peru on this endemic disease.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 5: Combined albendazole and praziquantel in subarachnoid ncc, ccc, lead application

Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 21,656 | 83,775 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 9,177 | 35,243 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 9,674 | 37,083 |
| Total direct costs | 40,507 | 156,101 |
| Indirect costs | 7,398 | 27,802 |
| Total indirect costs incurred | 47,905 | 183,903 |

Researcher: Héctor Hugo García Lescano

Project performance Term: September 2015 to January 2023

General objective of Project:

The main endpoint of the study is providing patients with disappearance of their parasitic injuries on neuroimaging six months after starting treatment. Secondary outcomes include decrease in the volume of parasite masses measured by MRI at 3 and 6 months after the start of treatment, clinical improvement assessed as the proportion of patients who were asymptomatic and without the need for additional antiparasitic treatment 6 months after treatment, the frequency of serious adverse events (SAEs) of the combination regimen compared to standard treatment; the decrease in serum levels of circulating parasite antigen at 3 and 6 months after the start of treatment, and the proportion of patients whose injuries healed and do not relapse 12 months after treatment.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 6: Understanding immune modulation in taenia solium neurocysticercosis by using a novel postoncosphere in vitro model
Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 96,299 | 360,543 |
| Training | 2,540 | 9,776 |
| Travel | 19,565 | 72,273 |
| Consulting | 28,000 | 102,816 |
| Equipment and/or supplies | 27,236 | 101,688 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 2,527 | 9,317 |
| Total direct costs | 176,167 | 656,413 |
| Indirect costs | 12,638 | 46,829 |
| Total indirect costs incurred | 188,805 | 703,242 |

Researcher: Manuela Renee Verastegui Pimentel

Project performance Term: May 2020 to April 2025

General objective of Project:

A new in vitro model of development of Taenia solium embryos is proposed, developed by the group, which allows to determine the specific differences of each stage in the expression of the antigen to identify the immunomodulatory molecules used by the parasite to survive. evading the host's immune response, with a focus on the recently described TGF- β mimic molecules that have been shown to play a significant role in parasite immunomodulation.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 7: Patient - Centered intervention to prevent tuberculosis among children < 5 years old

Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 58,268 | 219,395 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 3,270 | 12,342 |
| Total direct costs | 61,538 | 231,737 |
| Indirect costs | 10,847 | 39,875 |
| Total indirect costs incurred | 72,385 | 271,612 |

Researcher: Larissa Otero Vegas

Project performance Term: September 2018 to February 2024

General objective of Project:

Developing an intervention package to increase information, motivation, and memory to complete preventive therapy with isoniazid (IPT)(*) in children <5 years who have been prescribed IPT.

(*) Isoniazid preventive therapy (IPT) is a simple and cost-effective method that stops the activation of tuberculosis bacteria.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 8: A mobile phone short message service intervention to increase retention in HIV (Weltel Perú)

Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 112,712 | 421,939 |
| Training | 2,500 | 9,525 |
| Travel | 0 | 0 |
| Consulting | 3,068 | 11,410 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 664 | 2,509 |
| Contractual expenses | 0 | 0 |
| Others | 9,628 | 37,053 |
| Total direct costs | 128,572 | 482,436 |
| Indirect costs | 10,120 | 36,812 |
| Total indirect costs incurred | 138,692 | 519,248 |

Researcher: Luis Alberto Menacho Alvirio

Project performance Term: August 2020 to July 2025

General objective of Project:

Determining the effectiveness of SMS-based intervention delivered via a web-based system in increasing retention in HIV care compared to standard care. We will conduct a randomized controlled trial. The primary outcome will be retention in HIV care within 1 year of enrollment.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 9: The effect of strongyloides stercoralis on HTLV-1 disease progression
 Funded with U.S. Federal Funds under direct contract signed between National
 Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 26,216 | 98,620 |
| Training | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 10,923 | 40,878 |
| Lab and patient care services | 7,339 | 27,509 |
| Contractual expenses | 0 | 0 |
| Others | 2,390 | 9,015 |
| Total direct costs | 46,868 | 176,022 |
| Indirect costs | 37 | 136 |
| Total indirect costs incurred | 46,905 | 176,158 |

Researcher: Martin Montes Delgado

Project performance Term: March 2018 to February 2024

General objective of Project:

Testing two hypotheses: 1) Strongyloides infection stercoralis leads to a higher HTLV-1 proviral load, a higher number of infected cells, and early transformation of infected CD4+ T cells. We will compare the proviral load and the number of infected CD4+ T cells in the peripheral blood using CADM1 staining and loss of CD7 (an early marker of transformation). In patients coinfecting with HTLV-1/SS before and up to six months after treatment for strongyloidiasis; cases of coinfection with >5 years of follow-up or controls; Patient coinfecting with HTLV-1/SS followed prospectively. 2) Early cell transformation (CADM1 positive, CD7 low) is driven by the following mechanisms: a) Virus-driven lymphoproliferation (proviral load, spontaneous and antigen-driven lymphoproliferation); bacterial translocation and associated inflammation and/or expansion of regulatory T cells. These studies will test the importance of SS infection as a cofactor in lymphoproliferative disorders and will explore a rationale for more aggressive approaches to SS in HTLV-1 patients as well as in general populations.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 10: Using burden of treatment as a clinical indicator of barriers to multimorbidity management in Peru: A mixed methods A Mixed Approach
 Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 19,908 | 75,017 |
| Training | 0 | 0 |
| Travel | 681 | 2,493 |
| Consulting | 2,772 | 10,391 |
| Equipment and/or supplies | 3,348 | 12,468 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 27,363 | 100,958 |
| Total direct costs | 54,072 | 201,327 |
| Indirect costs | 4,693 | 17,198 |
| Total indirect costs incurred | 58,765 | 218,525 |

Researcher: Juan Jaime Miranda Montero

Project performance Term: September 2020 to June 2025

General objective of Project:

The Treatment will be used burden Questionnaire (TBQ) to evaluate BOT in patients with multimorbidity in Peru. Semi-structured interviews will also be conducted. Participants will be recruited from a variety of clinical and geographic settings. The TBQ will be applied to measure the total BOT as well as the BOT related to different dimensions of healthcare workload. Sociodemographic characteristics and other indicators of clinical outcomes will also be assessed. By collecting this information, we hope to better understand what patient-reported barriers to multimorbidity management exist in Peru and what subgroups of patients, particularly those in different healthcare sectors and geographic settings, are at higher risk of experiencing high BOT.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 11: 1/2 - Regional geohealth hub centered in Perú
Funded with U.S. Federal Funds under direct contract signed between National
Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 131,807 | 493,894 |
| Training | 0 | 0 |
| Travel | 120 | 450 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 30,252 | 112,218 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 73,988 | 274,864 |
| Others | 4,101 | 15,265 |
| Total direct costs | 240,268 | 896,691 |
| Indirect costs | 6,008 | 22,657 |
| Total indirect costs incurred | 246,276 | 919,348 |

Researcher: Stella María Hartinger Peña

Project performance Term: June 2022 to February 2027

General objective of Project:

Developing capacities in the investigation of air pollution in Peru and study its association with cardiovascular and respiratory conditions-including COVID-19- and Alzheimer's Disease (AD) where the association with air pollution is not well established.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 12: Planning an MD-MSC combined degree program focused on translational research to build the next generation of Physician-Scientist in Perú
Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 9,661 | 36,567 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Others | 2 | 6 |
| Total direct costs | <hr/> 9,663 | <hr/> 36,573 |
| Indirect costs | <hr/> 35 | <hr/> 133 |
| Total indirect costs incurred | <hr/> 9,698 | <hr/> 36,706 |

Researcher: Martin Montes Delgado

Project performance Term: July 2020 a March 2024

General objective of Project:

1) Developing the curricular design of the master's degree; 2) addressat both academic institutions the feasibility of accommodating dual accreditation requirements for a combined MD-MSC program; 3) develop the induction program for MD/MSC teachers, stimulating good tutoring practices towards the youngest learners; 4) pilot implementation of the curricular components of the master's degree; 5) Analyze strategies to optimize learner retention and the transition to scientific independence, with the participation of Peruvian stakeholders. After completing this planning process, we will be in an exceptional position to develop and implement a robust and highly competitive D43 application that will become a milestone in the capacity building of Peruvian doctors and scientists. As FIC alumni who returned to UPCH 15 years ago, we are eager to contribute to substantially enriching the research environment for our brilliant physician-scientists-in-training.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 13: Genomic epidemiology of campylobacter in poultry to enable the effective control of human campylobacteriosis in a middle-income country
Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 106,448 | 398,743 |
| Training | 615 | 2,325 |
| Travel | 4,494 | 17,033 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 15,370 | 57,170 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 264 | 980 |
| Total direct costs | 127,191 | 476,251 |
| Indirect costs | 7,613 | 28,446 |
| Total indirect costs incurred | 134,804 | 504,697 |

Researcher: Francesca Schiaffino Salazar

Project performance Term: August 2022 a June 2027

General objective of Project:

Researching into the genomic diversity of MDR Campylobacter colonization in chickens. This will be done with the overall goal of decreasing the MDR Campylobacter burden in human populations, through adequate control of Campylobacteriosis in poultry production and food processing. We believe that there are sufficient genomic features to identify distinct Campylobacter populations among small-scale and industrial-scale poultry products that may contribute significantly to human host-attribution disease models. We need to go beyond the epidemiology of risk factors within an environment harboring unlimited sources of Campylobacter.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 14: Equinococosis Quística Hepática: Evaluación preclínica de un nuevo enfoque tratamiento percutáneo

Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 0 | 0 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 0 | 0 |
| Indirect costs | 5 | 20 |
| Total indirect costs incurred | 5 | 20 |

Researcher: Saul Javier Santivañez Salazar

Project performance Term: March 2016 to February 2022

General objective of Project:

Evaluate a new one-step percutaneous treatment approach consisting of intracystic injection of albendazole sulfoxide (ABZ-SF), the active metabolic of ABZ. This procedure requires fewer resources and time than the PAIR, and also has the advantages that it would not be contraindicated by the presence of cystobiliary fistulas, and it should also be safer than oral therapy with ABZ since it avoids the systemic toxicity associated with prolonged oral therapy with ABZ. This Project includes 3 consecutive phases: In the first phase, two different doses of ABZ-SF are compared to determine the highest safe dose; finally, in the third phase, the minimum intracystic concentration of ABZ-SF necessary to achieve the success of the treatment will be determined.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 15: Alternative therapeutic approaches for the control of brain inflammation secondary to antihelminthic therapy in neurocysticercosis using a novel experimental
Funded with U.S. Federal Funds under direct contract signed between National
Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 74,806 | 279,373 |
| Training | 689 | 2,635 |
| Travel | 6,361 | 23,889 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 8,814 | 32,378 |
| Lab and patient care services | 4,863 | 18,445 |
| Contractual expenses | 0 | 0 |
| Others | 30,772 | 113,424 |
| Total direct costs | 126,305 | 470,144 |
| Indirect costs | 8,946 | 33,054 |
| Total indirect costs incurred | 135,251 | 503,198 |

Researcher: Gianfranco Arroyo Hurtado

Project performance Term: March 2019 to February 2025

General objective of Project:

This study protocol proposes to optimize this animal model and characterize the immunopathological processes associated with cystic infection of the CNS (study 1). Subsequently, and in conjunction with a combined anthelmintic regimen using albendazole and praziquantel, the model will be used to determine the appropriate doses of ETN (Study 2A) or MTX (Study 2B) in the control of the local acute inflammatory response resulting from therapy. anthelmintic in pigs with viable cerebral cysticercosis; Outcomes measured will include inflammatory markers, blood-brain barrier dysfunction/permeability, neuronal damage, and structural changes in brain tissue. Finally, in study 3, we will compare the optimal dose of ETN or MTX versus the standard anti-inflammatory regimen using the corticosteroid dexamethasone (DEX), in the control of pericystic inflammation using the same endpoints as studies 2A and 2B. We hope that our findings provide the evidence base for further investigation with ETN or MTX in controlled studies in patients with NCC.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 16: Training in infectious diseases in Perú - time for implementation research
 Funded with U.S. Federal Funds under direct contract signed between National
 Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 98,265 | 368,273 |
| Training | 156,562 | 586,820 |
| Travel | 41,894 | 157,507 |
| Consulting | 1,421 | 5,290 |
| Equipment and/or supplies | 36,185 | 135,409 |
| Lab and patient care services | 5,305 | 20,233 |
| Contractual expenses | 53,550 | 198,322 |
| Others | 37,717 | 141,861 |
| Total direct costs | 430,899 | 1,613,715 |
| Indirect costs i | 19,771 | 73,567 |
| Total indirect costs incurr | 450,670 | 1,687,282 |

Researcher: Héctor Hugo García Lescano

Project performance Term: July 1999 to February 2026

General objective of Project:

Training in infectious diseases is essential to build the research infrastructure in Peru, so that they can study infectious diseases of local importance. This training grant builds on a successful, long-standing, NIH-funded collaboration on training and research between the Universidad Peruana Cayetano Heredia (UPCH) in Lima, Peru, and the Johns Hopkins School of Public Health (JHSPH). We will develop and train students in short-term, medium-term, and long-term programs, both abroad and in Peru.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 17: A non-inferiority randomized single blind controlled trial comparing one and two dose regimes of oxfendazole

Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 20,804 | 78,790 |
| Training | 0 | 0 |
| Travel | 3,866 | 14,721 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Others | 79 | 298 |
| Total direct costs | 24,749 | 93,809 |
| Indirect costs | 12 | 43 |
| Total indirect costs incurred | 24,761 | 93,852 |

Researcher: Héctor Hugo García Lescano

Project performance Term: August 2023 to July 2028

General objective of Project:

In our experience in Cusco, Peru, nearly 40% of children treated with one dose of CBCT failed to achieve parasitological cure and 60% of them failed with a second dose of treatment. Oxfendazole (OXF) is a veterinary benzimidazole with a broad spectrum anthelmintic. Our group has extensive experience working with OXF through studies in cysticercosis by *Taenia solium*. Our preliminary studies in naturally infected animals show that OXF is also very effective against *Fasciola hepatica*. To date, we have completed animal toxicology and phase 1 studies of OXF in humans, which has confirmed its high bioavailability and, more importantly, its safety. These data strongly suggest that OXF is an excellent candidate for the treatment of human fascioliasis. We will compare two OXF regimens, a single dose of 20 mg/kg and two doses of 20 mg/kg, with the standard treatment of two doses of 10 mg/kg of CBCT for the treatment of children and adults with chronic *Fasciola hepatica* infection.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 18: Ensayo clínico controlado, aleatorizado, multicéntrico, de regímenes de dosis única y múltiple de oxfendazole
 Funded with U.S. Federal Funds under direct contract signed between National Institute of Health - NIH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 16,604 | 62,758 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 52 | 198 |
| Total direct costs | 16,656 | 62,956 |
| Indirect costs | 35 | 130 |
| Total indirect costs incurred | 16,691 | 63,086 |

Researcher: Héctor Hugo García Lescano

Project performance Term: September 2023 to May 2028

General objective of Project:

A randomized, double-blind, three-arm controlled trial in six research centers in two different geographic regions, three in India and three in Peru, to compare the efficacy and safety of a single-dose regimen with 20 mg/kg oxfendazole and a regimen with three similar doses over seven days (day 1, day 4 and day 7), with the most effective available antiparasitic regimen, combined with albendazole plus praziquantel for ten days in individuals with mild NCC (with one to two lesions).

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 19: Project of febrile illness surveillance in the Andean and Amazon countries
(Pisaac)

Funded with U.S. Federal Funds under direct contract signed between Centers For
Disease Control And Prevention and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 306,048 | 1,144,738 |
| Training | 23,582 | 87,961 |
| Travel | 3,342 | 12,676 |
| Consulting | 25,464 | 93,115 |
| Equipment and/or supplies | 294,579 | 1,101,489 |
| Lab and patient care services | 48,212 | 177,355 |
| Contractual expenses | 239,338 | 891,026 |
| Others | 33,502 | 125,644 |
| Total direct costs | 974,067 | 3,634,004 |
| Indirect costs | 50,671 | 189,560 |
| Total indirect costs incurred | 1,024,738 | 3,823,564 |

Researcher: Carlos Eduardo Zamudio Fuertes

Project performance Term: September 2021 to August 2025

General objective of Project:

Determining the etiology and epidemiology of influenza-like illnesses and severe acute respiratory diseases, with a special focus on COVID-19 in strategically selected regions of Peru and Ecuador, improve the capacity of laboratories to disease diagnosis, produce timely information and accurate surveillance data, and develop a workforce that can follow up on these measures.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 20: Cooperasalud: technical support for the consolidation of HIV prevention and control in the Peruvian Armed Forces

Funded with U.S. Federal Funds under direct contract signed between Centers For Disease Control And Prevention and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 126,322 | 473,975 |
| Training | 488 | 1,800 |
| Travel | 8,446 | 31,900 |
| Consulting | 15,476 | 58,740 |
| Equipment and/or supplies | 25,257 | 92,969 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 17,924 | 65,882 |
| Total direct costs | 193,913 | 725,266 |
| Indirect costs | 7,986 | 29,146 |
| Total indirect costs incurred | 201,899 | 754,412 |

Researcher: Claudia Lizzete Banda Flores

Project performance Term: September 2021 to September 2026

General objective of Project:

Improving human capacity, knowledge, awareness and proper diagnosis of fungal infections in Peru.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 21: Cooperasalud: technical support for the consolidation of HIV prevention and control in the Peruvian Armed Forces

Funded with U.S. Federal Funds under direct contract signed between Centers For Disease Control And Prevention and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 111,128 | 415,422 |
| Training | 0 | 0 |
| Travel | 10,515 | 39,125 |
| Consulting | 69,166 | 258,174 |
| Equipment and/or supplies | 62,918 | 239,543 |
| Lab and patient care services | 63 | 239 |
| Contractual expenses | 0 | 0 |
| Others | 27,921 | 103,939 |
| Total direct costs | 281,711 | 1,056,442 |
| Indirect costs | 127 | 477 |
| Total indirect costs incurred | 281,838 | 1,056,919 |

Researcher: Carlos Fernando Cáceres Palacios

Project performance Term: November 2019 to September 2023

General objective of Project:

This is a program that seeks to strengthen the resources and strategies for the prevention and control of HIV in the Armed Forces of Peru.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 22: Cooperasalud II: Technical Assistance To Strengthen Post-Pandemic HIV Prevention and Control Capacities In The Peruvian Armed Forces
 Funded with U.S. Federal Funds under direct contract signed directly between PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 15,106 | 57,104 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 8,506 | 31,848 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 1,734 | 6,477 |
| Total direct costs | 25,346 | 95,429 |
| Indirect costs | 35 | 131 |
| Total indirect costs incurred | 25,381 | 95,560 |

Researcher: Carlos Fernando Cáceres Palacios

Project performance Term: September 2023 to September 2027

General objective of Project:

In a new 4-year phase, COOPERASALUD II will provide technical assistance to Peruvian military personnel to improve the quality of HIV prevention care (from a combination prevention perspective); as well as the continuum of HIV care (testing, treatment and viral suppression), with special attention to HIV/TB co-infection, and addressing the stigma and discrimination surrounding the HIV epidemic among military personnel and their families. It also considers activities aimed at strengthening the military health system, including data management systems and the COPRECOS laboratory.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 23: Gut microbial and metabolic mediators of rotavirus vaccine response
 Funded with U.S. Federal Funds, Children´s Hospital los Ángeles and Universidad
 Peruana Cayetano Heredia Funded with U.S. Federal Funds under subcontract signed
 between Children´s Hospital Los Ángeles and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 37,727 | 141,536 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 696 | 2,475 |
| Equipment and/or supplies | 8,236 | 30,064 |
| Lab and patient care services | 4,227 | 15,624 |
| Contractual expenses | 0 | 0 |
| Others | 13,057 | 47,835 |
| Total direct costs | 63,943 | 237,534 |
| Indirect costs | 8,569 | 31,589 |
| Total indirect costs incurred | 72,512 | 269,123 |

Researcher: Theresa Jean Ochoa Woodell

Project performance Term: October 2021 to June 2023

General objective of Project:

The general objective of this multicenter study (USA, Panama and Peru) is to investigate the role and effect of intestinal bacteria in the response to the rotavirus vaccine according to the country and the different socioeconomic conditions of the population.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 24: Improving response to Malaria outbreaks in Amazon-basin countries
Funded with U.S. Federal Funds, under subcontract signed between Duke University
and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 78,525 | 295,179 |
| Training | 47 | 180 |
| Travel | 35,857 | 133,596 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 471 | 1,766 |
| Others | 36,140 | 137,028 |
| | 151,040 | 567,749 |
| Total direct costs | | |
| Indirect costs | 6,739 | 24,939 |
| | 157,779 | 592,688 |
| Total indirect costs incurred | | |

Researcher: Andrés Guillermo Lescano Guevara

Project performance Term: September 2021 to August 2026

General objective of Project:

Malaria is an endemic disease in areas of the Amazon in countries such as Peru, Brazil and Ecuador. A better knowledge of the distribution of climatic, ecological, social and community factors will allow the optimization of malaria outbreak prediction systems; as well as the timely and effective implementation of public health interventions. Objective: Improve the prediction of malaria incidence as part of an early warning system to inform interventions aimed at malaria control. Methodology: It is developed according to the 2 main specific objectives: 1) Evaluate the relationship between infrastructure, socioeconomic networks and migration across the international border (Brazil-Peru, Ecuador-Peru) with the incidence of malaria; First, the extraction of public data will be carried out in order to create a district database in the three countries and evaluate their relationships with malaria. Next, a community network sampling and key informant survey will be designed in two international transportation corridors to characterize community networks. Subsequently, malaria transmission patterns through community networks and whether connectivity at the district level predicts these community networks will be assessed. 2) Evaluate scenarios of potential interventions along the borders to jointly reduce malaria, first a selection of the communities and data collection will be made. Agent-based models (ABMs) will then be calibrated and validated. Subsequently, the results of the ABMs will be analyzed. Finally, there will be a dissemination of the information provided by the ABMs.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 25: Training - 2/2 Regional geohealth hub centered in Peru-US
 Funded with U.S. Federal Funds, under subcontract signed between Emory University
 and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 20,950 | 77,860 |
| Training | 44,561 | 165,959 |
| Travel | 10,608 | 40,196 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 6,846 | 25,939 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 11,458 | 42,494 |
| Total direct costs | 94,423 | 352,448 |
| Indirect costs | 3,626 | 13,524 |
| Total indirect costs incurred | 98,049 | 365,972 |

Researcher: Stella María Hartinger Peña

Project performance Term: January 2022 to February 2027

General objective of Project:

Strengthening research capabilities in topics related to environmental health and the association between environment air pollution and cardiovascular, respiratory, COVID-19 and Alzheimer's diseases in Peru. To achieve this, annual short courses in Peru, Chile and the United States of America, individual mentoring in research and graduate programs in public health in Peru are offered. The selection of participants will take place in Peru, Bolivia and Ecuador.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 26: Rapid point-of-care assay for diagnosis of Neurocysticercosis in seizure patients

Funded with U.S. Federal Funds, under subcontract signed between Kephera Diagnostics, LLC and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 10,221 | 38,678 |
| Training | 0 | 0 |
| Travel | 2,000 | 7,557 |
| Consulting | 1,654 | 6,237 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 1,505 | 5,676 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 15,380 | 58,148 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 15,380 | 58,148 |

Researcher: Héctor Hugo García Lescano

Project performance Term: September 2023 to April 2026

General objective of Project:

Developing a prototype point-of-care lateral flow serological test for neurocysticercosis. In Phase 1 of the Project, Kephera Inc. used recombinant and synthetic *T. solium* antigens corresponding to those used in EITB. These antigens have demonstrated high sensitivity and specificity in previous studies and, in combination, further increase sensitivity for the detection of viable single cysts, the most challenging manifestation of the disease. In Phase 2, we will collaborate with Kephera Inc in evaluating the lateral flow neurocysticercosis test in prospective studies in neurological patients with symptoms suggestive of neurocysticercosis.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 27: Proteome-wide characterization of T cell epitopes from mycobacterium tuberculosis in vaccination and active infection
Funded with U.S. Federal Funds, under subcontract signed between La Jolla Institute For Immunology and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 119,018 | 444,421 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 9,743 | 36,120 |
| Lab and patient care services | 17,952 | 67,055 |
| Contractual expenses | 0 | 0 |
| Others | 30,412 | 113,043 |
| Total direct costs | 177,125 | 660,639 |
| Indirect costs | 10,591 | 39,392 |
| Total indirect costs incurred | 187,716 | 700,031 |

Researcher: Cesar Ugarte Gil

Project performance Term: September 2021 to September 2024

General objective of Project:

This proposal deals with the discovery and validation of T cell epitopes presented by HLA class II that are derived from Mycobacterium tuberculosis. We will screen a library of 21,200 peptides in individuals with active TB disease, as well as individuals who have been vaccinated with BCG, all from the US, Peru, Moldova, Sri Lanka, and Sweden. These peptides will represent each individual ORF in the MTB genome, 2-10 per ORF depending on size, variants not fully conserved between the MTB strains considered, peptides contained only in BCG vaccine strains but not in MTB, and peptides from 15 MER overlapping by 10 covering 12 antigens currently.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 28: Análisis longitudinal de firmas inmunitarias (LMS) de células T específicas de M. tuberculosis

Funded with U.S. Federal Funds, under subcontract signed between La Jolla Institute For Immunology and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 46,164 | 173,855 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 157 | 600 |
| Lab and patient care services | 2,100 | 7,678 |
| Contractual expenses | 0 | 0 |
| Others | 4,575 | 17,287 |
| Total direct costs | 52,996 | 199,420 |
| Indirect costs | 850 | 3,091 |
| Total indirect costs incurred | 53,846 | 202,511 |

Researcher: César Ugarte Gil

Project performance Term: June 2022 to May 2027

General objective of Project:

It focuses on three (3) main objectives, referring to MTB exposure: Objective 1) active disease, characterized by uncontained symptomatic MTB infection, Objective 2) reactive (also known as “latent”) MTB, characterized by immune reactivity to MTB but no symptoms of disease, and Objective 3) adult BCG revaccination. For individuals with active disease, we will track IMS longitudinally over the course of treatment and identify markers that predict treatment outcome. Similarly, we will track the IMS of prophylactically treated “latent” individuals to determine who is most likely to benefit from treatment.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 29: Development and validation of an agent-based model to promote evidence-based control of taenia solium cysticercosis
 Funded with U.S. Federal Funds, under subcontract signed between Oregon Health & Science University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 160,449 | 601,786 |
| Training | 0 | 0 |
| Travel | 40,419 | 151,846 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 53,593 | 203,251 |
| Lab and patient care services | 7,826 | 29,172 |
| Contractual expenses | 0 | 0 |
| Others | 79,812 | 299,985 |
| Total direct costs | 342,099 | 1,286,040 |
| Indirect costs | 22,266 | 83,331 |
| Total indirect costs incurred | 364,365 | 1,369,371 |

Researcher: Héctor Hugo García Lescano
Project performance Term: July 2019 to June 2024

General objective of Project:

Developing an accurate transmission model that can efficiently identify those interventions with the highest probability of success for further testing in prospective field trials.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 30: Implementation of ring strategy for community engaged control of neurocysticercosis

Funded with U.S. Federal Funds, under subcontract signed between Oregon Health & Science University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 122,849 | 461,742 |
| Training | 1,074 | 4,044 |
| Travel | 6,854 | 25,750 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 29,745 | 112,676 |
| Lab and patient care services | 4,596 | 16,800 |
| Contractual expenses | 0 | 0 |
| Others | 55,814 | 208,881 |
| Total direct costs | 220,932 | 829,893 |
| Indirect costs | 11,999 | 44,788 |
| Total indirect costs incurred | 232,931 | 874,681 |

Researcher: Patricia Jannet García Funegra

Project performance Term: August 2019 a July 2024

General objective of Project:

Develop an adaptable approach for TA as a control program for Tsolium.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 31: Urine screening for early detection of subarachnoid neurocysticercosis
Funded with U.S. Federal Funds, under subcontract signed between Oregon Health &
Science University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 319,890 | 1,192,122 |
| Training | 7,640 | 28,771 |
| Travel | 29,197 | 110,398 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 28,627 | 106,864 |
| Lab and patient care services | 38,323 | 142,819 |
| Contractual expenses | 0 | 0 |
| Others | 83,693 | 314,101 |
| Total direct costs | 507,370 | 1,895,075 |
| Indirect costs | 33,637 | 124,821 |
| Total indirect costs incurred | 541,007 | 2,019,896 |

Researcher: Héctor Hugo García Lescano

Project performance Term: July 2018 to June 2024

General objective of Project:

This proposed cross-sectional study will focus on validating a new urinary antigen (AG) screening test for NCCSA in an endemic population, with confirmation by brain MRI, to understand the underlying prevalence of NCCSA. and testing at the community level. A defined group of urine samples will later be used to validate a prototype urine test format to be used at the point of care (PDA) that can be mass-produced.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 32: Next-generation sequencing diagnostics to identify etiologies of acute undifferentiated fever in the Peruvian Amazon

Funded with U.S. Federal Funds, under subcontract signed between Research Triangle Institute International and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 4,253 | 15,977 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 1,110 | 4,171 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 120 | 452 |
| Total direct costs | 5,483 | 20,600 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 5,483 | 20,600 |

Researcher: Francesca Falconi Agapito

Project performance Term: September 2023 to April 2025

General objective of Project:

Evaluating the usefulness of nanopore metagenomics in the absence of a diagnosis, using samples that tested negative for DENV, ZIKV, YFV, CHIKV, malaria and leptospirosis; evaluating the added value of nanopore metagenomics for samples with an existing diagnosis in DENV positive samples and evaluating the cost-effectiveness of nanopore metagenomic diagnosis and surveillance in Peru.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 33: Fend for tuberculosis
Funded with U.S. Federal Funds under subcontract signed between Rutgers The State
University of New Jersey and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 242,839 | 911,175 |
| Training | 1,726 | 6,385 |
| Travel | 540 | 1,987 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 57,810 | 220,745 |
| Lab and patient care services | 48,206 | 180,986 |
| Contractual expenses | 0 | 0 |
| Others | 36,461 | 137,950 |
| Total direct costs | 387,582 | 1,459,228 |
| Indirect costs | 22,802 | 86,414 |
| Total indirect costs incurred | 410,384 | 1,545,642 |

Researcher: César Augusto Ugarte Gil

Project performance Term: June 2020 to May 2025

General objective of Project:

Support early proof-of-principle studies to evaluate early stage tuberculosis such as: tests, assays, diagnostic strategies and provide feedback to diagnostic developers on the performance of the technology and potential strategies for use in endemic settings. The end of this “early stage” diagnostic initiative refers to a diagnostic that has advanced to the stage where a prototype is ready and available for evaluation, but is not currently used in clinical care and treatment decisions for tuberculosis.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 34: Historia natural del SARS-CoV-2 en comparación con el virus de la
influenza A

Funded with U.S. Federal Funds, under subcontract signed between ST Jude
Childrens Research Hospital and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 137 | 507 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 137 | 507 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 137 | 507 |

Researcher: Patricia Jannet García Funegra

Project performance Term: June 2020 to December 2022

General objective of Project:

The main objectives are to: (1) document clinical outcomes and risk factors for mild, moderate, and severe disease in persons with SARS-CoV-2 or influenza infection; (2) define the magnitude, quality, and longevity of immune responses to SARS-CoV-2 or influenza infection; (3) characterize the levels and duration of viral shedding in persons infected with SARS-CoV-2 or influenza and; (4) characterize phenotypic and genotypic changes in SARS-CoV-2 and influenza viruses during the course of infection by next-generation sequencing; (5) characterize the levels and duration of viral shedding in persons infected with SARS-CoV-2 or influenza and; (6) characterize phenotypic and genotypic changes in SARS-CoV-2 and influenza viruses during the course of infection by next generation sequencing.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 35: Enabling Infectious Disease Research Capacity in The Peruvian Amazon
Funded with U.S. Federal Funds, under subcontract signed between The
Administrators of The Tulane Educational Fund (DBA Tulane University) and
Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 10,163 | 38,483 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 10,163 | 38,483 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 10,163 | 38,483 |

Researcher: Francesca Schiaffino Salazar

Project performance Term: April 2018 to February 2023

General objective of Project:

This project proposes a collaborative research training program that strengthens the capacity of an institution] to carry out research on infectious diseases in Iquitos, Peru that focuses on 1) endemic or life-threatening emerging diseases of infectious diseases 2) neglected tropical diseases 3) frequent infections as co- infections in HIV-infected individuals or 4) infections associated with noncommunicable diseases that are of public health importance.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 36: How land use change transforms the landscape of vector-borne disease
 Funded with U.S. Federal Funds, under subcontract signed between The Board Of
 Trustees Of The Leland Stanford Juner University and Universidad Peruana Cayetano
 Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 34,463 | 128,674 |
| Training | 0 | 0 |
| Travel | 15,672 | 57,440 |
| Consulting | 3,323 | 12,080 |
| Equipment and/or supplies | 28,794 | 107,352 |
| Lab and patient care services | 1,534 | 5,580 |
| Contractual expenses | 0 | 0 |
| Others | 16,859 | 61,688 |
| Total direct costs | 100,645 | 372,814 |
| Indirect costs | 8,036 | 30,341 |
| Total indirect costs incurred | 108,681 | 403,155 |

Researcher: Andrés Guillermo Lescano Guevara

Project performance Term: September 2021 to August 2025

General objective of Project:

The proposed research addresses the dynamic relationship between land-use change and vector-borne diseases by understanding how changes in environmental conditions affect the vector, host, and pathogen traits they drive. First, how environmental mechanisms translate into variations in observable disease incidence across large gradients in land use remains an understudied link between ecology, land use policy, and public health. Second, how these emergent large-scale dynamics of disease incidence across land use and over time. Third, a case study in the Peruvian Amazon will explain how the effects of environmental change on vector, host, and pathogen populations are combined to determine the effects of land use on vector-borne diseases at the local scale.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 37: HIV risk and psychosocial health among transgender women in Perú
 Funded with U.S. Federal Funds, under subcontract signed between The Childrens
 Hospital Corporation D/B/A Boston CH and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 18,792 | 69,989 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 7,548 | 27,460 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 779 | 2,866 |
| Total direct costs | 27,119 | 100,315 |
| Indirect costs | 1,982 | 7,537 |
| Total indirect costs incurred | 29,101 | 107,852 |

Researcher: Alfonso Alberto Silva Santisteban Portella

Project performance Term: August 2019 to July 2023

General objective of Project:

A first phase that consists of formative/qualitative research to explore issues related to the psychosocial vulnerability of young trans women. Likewise, surveys and collection of samples to determine the prevalence of HIV, hepatitis B and C and associated factors. The design of the implementation and instruments of the second phase will be carried out taking into account the results of the first phase.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 38: Acceptability, feasibility, and preliminary impact of a web-based, HIV prevention toolkit with Cisge

Funded with U.S. Federal Funds, under subcontract signed between The Florida International University Board of Trus and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 38,291 | 143,678 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 11,516 | 42,784 |
| Lab and patient care services | 2,152 | 7,955 |
| Contractual expenses | 0 | 0 |
| Others | 11,663 | 42,963 |
| Total direct costs | 63,622 | 237,380 |
| Indirect costs | 4,547 | 16,926 |
| Total indirect costs incurred | 68,169 | 254,306 |

Researcher: Andrés Guillermo Lescano Guevara

Project performance Term: July 2021 to June 2024

General objective of Project:

Testing an intervention for gay male couples to see if it helps them prevent HIV/STIs. The intervention is a website with 5 modules designed for gay couples.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 39: Using the mycobacterium tuberculosis genome to predict tuberculosis pathology

Funded with U.S. Federal Funds, under subcontract signed between The John Hopkins University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 133,532 | 499,924 |
| Training | 5,000 | 19,250 |
| Travel | 0 | 0 |
| Consulting | 30,000 | 113,580 |
| Equipment and/or supplies | 35,445 | 132,575 |
| Lab and patient care services | 6,377 | 23,871 |
| Contractual expenses | 0 | 0 |
| Others | 10,030 | 37,743 |
| Total direct costs | 220,384 | 826,943 |
| Indirect costs | 14,974 | 55,584 |
| Total indirect costs incurred | 235,358 | 882,527 |

Researcher: Mirko Juan Zimic Peralta

Project performance Term: April 2021 to March 2025

General objective of Project:

Combining genome sequencing data of the tuberculosis (TB) pathogen at the population level with radiological data and determine the bacterial genomic form of the pathology in tuberculosis in Peru at the population level for 20 years and infer phylogenetically what genetic background is associated with the acquisition of drug resistance; then confirm these findings in the laboratory and in a similar collection of Moldovan datasets of >3000 strains.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 40: Predictors of cardiomyopathy progression in a chagas disease cohort in
Bolivia

Funded with U.S. Federal Funds, under subcontract signed between The John Hopkins
University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 16,331 | 60,763 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 7,321 | 27,148 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 1,157 | 4,231 |
| Total direct costs | 24,809 | 92,142 |
| Indirect costs | 2,907 | 10,882 |
| Total indirect costs incurred | 27,716 | 103,024 |

Researcher: Manuela Renee Verastegui Pimentel

Project performance Term: February 2014 to June 2024

General objective of Project:

We intend to examine biomarkers in multiple categories simultaneously to allow a full assessment of their relative usefulness, individually and in combination, in a cohort study recruited from two populations, (1) hyperendemic villages where >95% of the Adults have T. cruzi infection and 17% of infected individuals > 30 years of age have electrocardiographic abnormalities characteristic of Chagasic cardiomyopathy and (2) a large public hospital in the city of Santa Cruz, where it is expected that > 50% of heart patients have Chagas heart disease. The primary outcome measure will be the progression of Chagasic cardiomyopathy over 4 years of follow-up.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 41: Infectious diseases training program in Bolivia: south - south training with
Perú

Funded with U.S. Federal Funds, under subcontract signed between The John Hopkins
University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 34,304 | 128,091 |
| Training | 48,083 | 180,771 |
| Travel | 8,386 | 31,488 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 400 | 1,480 |
| Lab and patient care services | 2,079 | 8,000 |
| Contractual expenses | 0 | 0 |
| Others | 13,459 | 50,510 |
| Total direct costs | 106,711 | 400,340 |
| Indirect costs | 7,123 | 26,622 |
| Total indirect costs incurred | 113,834 | 426,962 |

Researcher: Héctor Hugo García Lescano

Project performance Term: May 2015 to December 2024

General objective of Project:

The general objective of our proposal is to develop and build a long-term sustainable training program in tropical infectious diseases in Bolivia. Our goal is to meet the needs of marginalized areas, train a group of professionals, strengthen local institutions, and improve research methodologies, in order to improve the quality and impact of research.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 42: Novel nanoparticular diagnostics for Cerebral toxoplasmosis and Chagas in
HIV patients living in Latinoamerica
Funded with U.S. Federal Funds, under subcontract signed between The John Hopkins
University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 44,439 | 167,884 |
| Training | 0 | 0 |
| Travel | 188 | 716 |
| Consulting | 93 | 350 |
| Equipment and/or supplies | 5,637 | 21,013 |
| Lab and patient care services | 10 | 40 |
| Contractual expenses | 0 | 0 |
| Others | 3,837 | 14,290 |
| Total direct costs | 54,204 | 204,293 |
| Indirect costs | 5,339 | 19,891 |
| Total indirect costs incurred | 59,543 | 224,184 |

Researcher: Mirko Juan Zimic Peralta

Project performance Term: June 2018 to May 2023

General objective of Project:

This project will help define the clinical spectrum of HIV-associated neurological disease in Latin America. The Project will employ innovative diagnostic techniques to distinguish between CNS Chagas disease, TBM, ET and other CNS infections. Where multiple pathogens are endemic and rapidly fatal, faster, more sensitive and specific tests could accelerate the initiation of targeted therapy and thus achieve early patient recovery. A definitive diagnosis of ET, TBM and CNS Chagas in an accessible body fluid, such as urine, could allow immediate initiation of effective treatment and avoid invasive and more indirect diagnostic tests.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 43: Research training in chronic, non-communicable respiratory diseases in
Perú

Funded with U.S. Federal Funds, under subcontract signed between The John Hopkins
University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 19,214 | 71,868 |
| Training | 10,618 | 40,263 |
| Travel | 11,751 | 43,145 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 532 | 2,000 |
| Total direct costs | 42,115 | 157,276 |
| Indirect costs | 2,193 | 8,248 |
| Total indirect costs incurred | 44,308 | 165,524 |

Researcher: Stella María Hartinger Peña

Project performance Term: April 2020 to May 2025

General objective of Project:

The objective of this training program is to provide high caliber multidisciplinary training opportunities to young Peruvian researchers in research on environmental exposure and chronic respiratory diseases. Specifically, this program will focus on building research and training capacity to address environmental risk factors (ambient air pollution, household air pollution, smoking, occupational exposures) that are driving the epidemic of chronic respiratory diseases (asthma, COPD, EPI) in Peru. In addition, the program will provide intensive training opportunities and build training capacity in a variety of scientific disciplines (clinical epidemiology, exposure assessment, efficacy trials, implementation science) relevant to addressing this emerging threat.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 44: Investigating platelets in the innate immune response to tuberculosis
 Funded with U.S. Federal Funds, under subcontract signed between The John Hopkins
 University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 19,785 | 72,842 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 5,920 | 21,935 |
| Lab and patient care services | 13,152 | 48,381 |
| Contractual expenses | 0 | 0 |
| Others | 428 | 1,577 |
| Total direct costs | 39,285 | 144,735 |
| Indirect costs | 537 | 1,981 |
| Total indirect costs incurred | 39,822 | 146,716 |

Researcher: Mirko Juan Zimic Peralta

Project performance Term: September 2021 to August 2023

General objective of Project:

Correlating changes in markers of platelet activation with measures of tissue destruction and clinical and radiological outcomes, focusing on markers identified through our in vitro and RNASeq work. The proposed study utilizes techniques such as light transmission aggregation that are used in other areas of research but have been little used in infections and, to our knowledge, never in tuberculosis.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 45: Tuberculosis research project UPCH-OSU
Funded with U.S. Federal Funds, under subcontract signed between The Ohio State
University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 0 | 0 |
| Training | 47,839 | 179,730 |
| Travel | 367 | 1,372 |
| Consulting | 27,628 | 104,753 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 98 | 366 |
| Contractual expenses | 0 | 0 |
| Others | 2,811 | 10,528 |
| Total direct costs | 78,743 | 296,749 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 78,743 | 296,749 |

Researcher: César Augusto Ugarte Gil

Project performance Term: January 2021 to December 2023

General objective of Project:

Evaluating the diagnostic validity of Xpert Xpress SARS-CoV-2 by comparing it with a composite reference standard (RT-PCR, tomography, epidemiological clinical history and clinical symptoms).

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 46: Enabling infectious disease research capacity in the Peruvian Amazon
Funded with U.S. Federal Funds, under subcontract signed between The Rector and
Visitors of the University of Virginia and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 3,548 | 13,576 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 3,548 | 13,576 |
| Indirect costs | 388 | 1,457 |
| Total indirect costs incurred | 3,936 | 15,033 |

Researcher: Andrés Guillermo Lescano Guevara

Project performance Term: March 2023 to December 2027

General objective of Project:

This project proposes a collaborative research training program that strengthens the capacity of an institution in a low or medium-income country to carry out research on infectious diseases that focuses on 1) endemic or life-threatening emerging diseases of infectious diseases 2) neglected tropical diseases 3) frequent infections as co- infections in HIV-infected individuals or 4) infections associated with noncommunicable diseases that are of public health importance in low- and middle-income countries.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 47: Genomic Epidemiology of Campylobacter to Improve Disease Control in Low- and Middle-Income Countries
Funded with U.S. Federal Funds, under subcontract signed between The Rector and Visitors of the University of Virginia and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 18,212 | 68,459 |
| Training | 0 | 0 |
| Travel | 202 | 747 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 18,414 | 69,206 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 18,414 | 69,206 |

Researcher: Francesca Schiaffino Salazar

Project performance Term: March 2023 to February 2026

General objective of Project:

Report on specific disease control measures to reduce the impact of campylobacteriosis and human MDR Campylobacter in low- and middle-income countries.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 48: HIV prevention and care for Peruvian MSM and transgender women
Funded with U.S. Federal Funds, under subcontract signed between The Regents of
the University of California and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 140 | 529 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 4 | 15 |
| Total direct costs | <hr/> 144 | <hr/> 544 |
| Indirect costs | <hr/> 0 | <hr/> 0 |
| Total indirect costs incurred | <hr/> 144 | <hr/> 544 |

Researcher: Carlos Fernando Cáceres Palacios

Project performance Term: February 2016 to December 2022

General objective of Project:

Improving the quality of HIV prevention and treatment care aimed at the MSM and trans women population in the intervention area; in the context of adequate attention to the needs of the population, taking as a framework an approach of the right to health in the context of the continuum of HIV prevention and care.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 49: Integrating smartphone photography for Trachoma, smartphone visual acuity assessment, and mobile autorefraction to enhance community-based public health monitoring

Funded with U.S. Federal Funds, under subcontract signed between The Regents of the University of California and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 52,215 | 194,176 |
| Training | 0 | 0 |
| Travel | 1,670 | 6,198 |
| Consulting | 2,293 | 8,492 |
| Equipment and/or supplies | 1,682 | 6,322 |
| Lab and patient care services | 5,769 | 21,780 |
| Contractual expenses | 0 | 0 |
| Others | 11,385 | 42,388 |
| Total direct costs | 75,014 | 279,356 |
| Indirect costs | 3,697 | 13,686 |
| Total indirect costs incurred | 78,711 | 293,042 |

Researcher: Andrés Guillermo Lescano Guevara

Project performance Term: September 2021 to December 2023

General objective of Project:

In this project, we propose to add modules for other trachoma- related conditions, add the ability to collect data on other outcomes such as photography and conjunctival swabs, take advantage of smartphone barcode scanning capabilities to facilitate sample management and incorporate Peek Acuity to measure visual acuity. All these improvements to the Tropical Data application could improve its use as a survey instrument by health ministries around the world. Objective Evaluate the feasibility of a mobile application that integrates the Cellscope and other functionalities in the Tropical Data platform using different types of smartphones, in a variety of field conditions and communities.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 50: South American Program In Hiv Prevention Research (SAPHIR)
Funded with U.S. Federal Funds, under subcontract signed between The Regents of
the University of California and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 14,608 | 54,316 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 5,000 | 17,995 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 19,608 | 72,311 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 19,608 | 72,311 |

Researcher: César Paul Eugenio Carcamo Cavagnaro

Project performance Term: June 2021 to March 2026

General objective of Project:

Provide developing researchers from the United States of America with a structured education and training program based on a specific research topic within the field of human immunodeficiency virus HIV prevention in Latin America. Participants in the SAPHIR program are paired with research mentors from the United States and Latin America to develop an independent research program that incorporates both secondary analysis of existing data and the design of an original research study protocol. Potential research topics include behavioral, epidemiological, clinical and laboratory questions related to HIV human immunodeficiency virus prevention in specific Latin American contexts.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 51: University of California global health institute program for fellows and scholars

Funded with U.S. Federal Funds, under subcontract signed between The Regents Of The University Of California, San Francisco and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 4,579 | 17,334 |
| Training | 5,250 | 20,302 |
| Travel | 0 | 0 |
| Consulting | 3,300 | 12,101 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 1 | 3 |
| Total direct costs | 13,130 | 49,740 |
| Indirect costs | 402 | 1,483 |
| Total indirect costs incurred | 13,532 | 51,223 |

Researcher: Andrés Guillermo Lescano Guevara

Project performance Term: April 2012 to June 2025

General objective of Project:

Glocal is a program of a consortium of four universities in California, USA, funded by the US National Institutes of Health with the objective of providing 12-month mentored research internships in Peru to researchers North Americans or Peruvians.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 52: Aplicación de nuevos biomarcadores para medir los impactos en la salud del cambio antropogénico en la Amazonia

Funded with U.S. Federal Funds, under subcontract signed between The Research Foundation For Suny, University AT-AL and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 4,819 | 18,233 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 4,819 | 18,233 |
| Indirect costs | 70 | 263 |
| Total indirect costs incurred | 4,889 | 18,496 |

Researcher: Antonio Bernabé Ortiz

Project performance Term: August 2022 to August 2024

General objective of Project:

Assessing changes in adult dietary patterns and cardiometabolic disease risk profiles (hbA1C, HDL-C, LDL-C, height, weight, waist-to-hip ratio, blood pressure, and triglycerides) associated with the construction of the Inter-Oceanic Highway (IOH) through the Southern Peruvian Amazon by measuring these biomarkers of nutritional transition and complementary dietary survey data.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 53: Peruvian/Brazilian Amazon center of excellence in malaria (transmission dynamics of residual Malaria in the Amazon)
Funded with U.S. Federal Funds, under subcontract signed between The University Of California San Diego and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 0 | 0 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 578 | 2,158 |
| Total direct costs | <hr/> 578 | <hr/> 2,158 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | <hr/> 578 | <hr/> 2,158 |

Researcher: Dionicia Gamboa Vilela

Project performance Term: July 2017 to March 2024

General objective of Project:

The main objective is to identify the risk factors for infection and residual disease of Malaria, both at the individual and family level, it will provide samples of parasites for detailed molecular analyzes of the population and epidemiological data to develop new mathematical models of malaria transmission.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 54: Long-term mental health symptoms and psychological rehabilitation among peruvian COVID - 19 survivors

Funded with U.S. Federal Funds, under subcontract signed between The University Of North Carolina At Chapel Hill and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 1,173 | 4,342 |
| Training | 38,330 | 142,083 |
| Travel | 0 | 0 |
| Consulting | 745 | 2,870 |
| Equipment and/or supplies | 749 | 2,755 |
| Lab and patient care services | 195 | 720 |
| Contractual expenses | 0 | 0 |
| Others | 2,860 | 10,852 |
| Total direct costs | 44,052 | 163,622 |
| Indirect costs | 3,809 | 13,885 |
| Total indirect costs incurred | 47,861 | 177,507 |

Researcher: Andrés Guillermo Lescano Guevara

Project performance Term: June 2022 to June 2024

General objective of Project:

Determining whether on the wake of COVID-19, people are at greater risk of developing mental health disorders.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 55: An Integrated Approach to Understand and Diagnose congenital Chagas disease

Funded with U.S. Federal Funds, under subcontract signed between The University Of North Carolina At Chapel Hill and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 2,841 | 10,675 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 4,425 | 16,575 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 7,266 | 27,250 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 7,266 | 27,250 |

Researcher: Mirko Juan Zimic Peralta

Project performance Term: June 2022 to May 2027

General objective of Project:

Identifying risk factors for vertical transmission of Chagas disease, understanding its pathogenesis and developing better diagnosis for early childhood and assessing risk factors, including maternal medical and demographic history, maternal genetics and immunology and parasite genetics.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 56: Multidisciplinary Training Program on Neuropsychiatry and behavioral disorders in First Nations (NEUFIN)
 Funded with U.S. Federal Funds, under subcontract signed between The University of Texas Hilth Science Center at San Antonio and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 23,464 | 87,862 |
| Training | 43,568 | 162,949 |
| Travel | 7,252 | 27,798 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 1,788 | 6,541 |
| Total direct costs | 76,072 | 285,150 |
| Indirect costs | 4,055 | 14,655 |
| Total indirect costs incurred | 80,127 | 299,805 |

Researcher: Carla María Gallo López

Project performance Term: September 2021 to July 2026

General objective of Project:

We will continue developing capacities and training Quechua neuroscientists in clinical research applications of neuroimaging, genetics, epidemiology, neuropsychology and neuromodulation. We will also create customized training environments and an online innovation ecosystem to support the capacity and professional development of Quechua neuroscientists after completing their initial degree.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 57: Isolation and identification of CXCR4 and CXCR7 agonists from traditional phytopharmaceuticals as potential novel drugs for mental disorders
Funded with U.S. Federal Funds, under subcontract signed between The University of Texas Hilth Science Center at San Antonio and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 21,600 | 81,637 |
| Training | 0 | 0 |
| Travel | 9,764 | 37,130 |
| Consulting | 4,500 | 16,974 |
| Equipment and/or supplies | 164 | 600 |
| Lab and patient care services | 4,019 | 14,600 |
| Contractual expenses | 0 | 0 |
| Others | 1,413 | 5,166 |
| Total direct costs | 41,460 | 156,107 |
| Indirect costs | 438 | 1,585 |
| Total indirect costs incurred | 41,898 | 157,692 |

Researcher: Carla María Gallo López

Project performance Term: January 2021 a July 2024

General objective of Project:

The main objective is to perform a bioassay-guided fractionation of 15 CXCR4 or CXCR7 active extracts, replicate and determine the molecular structure of the isolated active compound(s), and provide outstanding students located in Peru with the opportunity to conduct their thesis work, present their results at major international conferences, and train in drug discovery research approaches.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 58: Colonización del intestino con patógenos con resistencia antimicrobiana
Funded with U.S. Federal Funds, under subcontract signed between Tufts University
and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 22 | 80 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | <u>22</u> | <u>80</u> |
| Indirect costs | 348 | 1,332 |
| Total indirect costs incurred | <u>370</u> | <u>1,412</u> |

Researcher: Mónica Jehnny Pajuelo Travezaño

Project performance Term: May 2020 to August 2022

General objective of Project:

In addressing basic epidemiologic questions about the prevalence of ESBL-E and CIP-C in healthy children under 2 years of age in Peru, we will conduct a cross-sectional, age-stratified pilot study in three peri-urban communities in Peru: (1) Villa El Salvador, a slum in Lima, Peru, where we have worked since the 1980s, (2) Iquitos, where we have worked since the early 2000s, and (3) Arequipa. We will evaluate the presence of culturable ESBL-E and CIP-C in the stool of children and determine whether the prevalence differs by age and study site. We will collect stool samples from study subjects and sociodemographic information.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 59: Prevalence and incidence of neonatal HSV (herpes simplex) in pre-term infants

Funded with U.S. Federal Funds, under subcontract signed between Universidad de Alabama and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 521 | 2,080 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 4,000 | 15,264 |
| Contractual expenses | 0 | 0 |
| Others | 2,200 | 8,097 |
| Total direct costs | 6,721 | 25,441 |
| Indirect costs | 20 | 76 |
| Total indirect costs incurred | 6,741 | 25,517 |

Researcher: César Paul Eugenio Carcamo Cavagnaro

Project performance Term: August 2016 to December 2022

General objective of Project:

Estimating the incidence of neonatal herpes by combining two components. The first will make it possible to determine the prevalence of HSV infection confirmed by PCR in neonates with a suspected diagnosis of sepsis or meningitis (MSS). The second component will estimate the incidence of SSM in a prospective cohort of newborns.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 60: A prospective study of Acute Flaccid Myelitis (AFM) to define natural
Funded with U.S. Federal Funds, under subcontract signed between Universidad de
Alabama and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 35,041 | 131,415 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 252 | 964 |
| Equipment and/or supplies | 1,527 | 5,672 |
| Lab and patient care services | 1,814 | 6,861 |
| Contractual expenses | 0 | 0 |
| Others | 7,531 | 28,077 |
| Total direct costs | 46,165 | 172,989 |
| Indirect costs | 5,768 | 21,692 |
| Total indirect costs incurred | 51,933 | 194,681 |

Researcher: Theresa Jean Ochoa Woodell

Project performance Term: July 2019 to May 2024

General objective of Project:

Prospective, observational and multicenter study that seeks to describe the clinical spectrum of acute flaccid myelitis (AFM) in pediatric patients and its possible association with infectious processes. This study will enroll patients with suspected AFM and their household contacts. Biological samples will be collected from the enrolled subjects to constitute a biorepository, which will serve for future studies aimed at studying the etiology, pathophysiology and genetics of AFM; as well as for the development of diagnostic methods, vaccines and treatment for this condition.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 61: Conocimientos, actitudes y exposición frente al virus hepatitis A en
estudiantes de medicina de una universidad privada de Lima, Perú
Funded with U.S. Federal Funds, under subcontract signed between Universidad de
Alabama and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 0 | 0 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 1,312 | 4,872 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 1,312 | 4,872 |
| Indirect costs | 11 | 40 |
| Total indirect costs incurred | 1,323 | 4,912 |

Researcher: Helga De Los Ángeles Muñoz Cisneros

Project performance Term: April 2023 to April 2026

General objective of Project:

Determining the level of knowledge about hepatitis A virus infection in medical students of a university in Lima, Peru, their vaccination rate against hepatitis A virus, and their IgG serology for hepatitis A virus. The study will be descriptive, observational, longitudinal, prospective; the inclusion criteria will be owned by the faculty of Medicine of the University, to have satisfactorily completed the course of Structure and function of the Locomotor and Digestive systems and to be enrolled in the faculty during the period in which the survey is carried out.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 62: Cómo la pandemia de la COVID -19 afectó la vida y el trabajo de los agentes comunitarios de salud
Funded with U.S. Federal Funds, under subcontract signed between Universidad de Arizona and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 65 | 250 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | <hr/> 65 | <hr/> 250 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | <hr/> 65 | <hr/> 250 |

Researcher: Magaly Marlitz Blas Blas

Project performance Term: August 2021 to June 2022

General objective of Project:

The objective of this study is to investigate how the pandemic affected the life and work of community health workers - CHWs.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 63: Efectos COVID -19 en adolescentes de la región Amazónica de Loreto
Funded with U.S. Federal Funds, under subcontract signed between Universidad de
Arizona and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 2,537 | 9,529 |
| Training | 0 | 0 |
| Travel | 5,934 | 22,056 |
| Consulting | 1,331 | 5,000 |
| Equipment and/or supplies | 137 | 502 |
| Lab and patient care services | 21 | 80 |
| Contractual expenses | 0 | 0 |
| Others | 866 | 3,215 |
| Total direct costs | 10,826 | 40,382 |
| Indirect costs | 35 | 129 |
| Total indirect costs incurred | 10,861 | 40,511 |

Researcher: Magaly Marlitz Blas Blas

Project performance Term: January 2023 to January 2024

General objective of Project:

Evaluating the impact that COVID-19 has had on education and adolescent pregnancy in peri-urban areas of the Loreto region, in the districts of Nauta, Parinari and Saquena. Focusing on the effect that school closures have had on adolescents and the long-term impacts on their reproductive health.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 64: Conocimientos, prácticas y actitudes hacia la salud bucal infantil
Funded with U.S. Federal Funds, under subcontract signed between Universidad de California and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 111 | 411 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | <hr/> 111 | <hr/> 411 |
| Indirect costs | <hr/> 960 | <hr/> 3,617 |
| Total indirect costs incurred | <hr/> 1,071 | <hr/> 4,028 |

Researcher: Patricia Jannet García Funegra

Project performance Term: July 2021 to June 2023

General objective of Project:

Identifying possible barriers and facilitators to include children's oral health in the routine pediatric check-up performed by nurses in the framework of the National Program for the Control and Growth of Children under 5 Years of Age (CRED), especially during the first three years of life.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 65: CCASANET: Improving the diagnosis of HIV-associated neurocognitive disorder (hand) in Latin America: A multimodal approach to hand in Perú
Funded with U.S. Federal Funds, under subcontract signed between University of North Carolina and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in | Amount in |
|--------------------------------------|---------------|----------------|
| | US\$ | S/ |
| <u>Direct costs</u> | | |
| Employee benefits | 30,988 | 116,005 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 3,142 | 11,924 |
| Lab and patient care services | 4,708 | 17,609 |
| Contractual expenses | 0 | 0 |
| Others | 3,398 | 12,650 |
| Total direct costs | 42,236 | 158,188 |
| Indirect costs | 1,439 | 5,280 |
| Total indirect costs incurred | 43,675 | 163,468 |

Researcher: Patricia Jannet García Funegra

Project performance Term: July 2022 to June 2025

General objective of Project:

Adapt a digital tool (on tablets) currently used for early Alzheimer screening, and validate its use in TNAV in Peru. As a secondary objective, risk factors for TNAV will be identified and used to build a predictive statistical model for TNAV in Peru that can identify modifiable factors. As a final objective, the tools will be implemented, evaluated and optimized through iterative rounds of interviews with PLWHA care providers.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 66: Evaluación de urgencias, emergencias y atención neuroquirúrgica esencial en el Perú Funded with U.S. Federal Funds, under subcontract signed between Universidad de Duke and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 18,830 | 71,503 |
| Training | 7,800 | 29,839 |
| Travel | 339 | 1,288 |
| Consulting | 23,080 | 87,012 |
| Equipment and/or supplies | 1,380 | 5,277 |
| Lab and patient care services | 334 | 1,280 |
| Contractual expenses | 0 | 0 |
| Others | 1,055 | 4,070 |
| Total direct costs | 52,818 | 200,269 |
| Indirect costs | 9,454 | 36,288 |
| Total indirect costs incurred | 62,272 | 236,557 |

Researcher: Patricia Jannet García Funegra

Project performance Term: April 2019 to April 2023

General objective of Project:

Evaluating the feasibility and effectiveness (including an indirect cost analysis) of the combination of the pocket colposcope and thermocoagulator.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 67: Evaluación de urgencias, emergencias y atención neuroquirúrgica esencial en el Perú

Funded with U.S. Federal Funds, under subcontract signed between Universidad de Harvard and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 0 | 0 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 2,000 | 7,272 |
| Contractual expenses | 0 | 0 |
| Others | 565 | 2,182 |
| Total direct costs | 2,565 | 9,454 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 2,565 | 9,454 |

Researcher: Patricia Jannet García Funegra

Project performance Term: July 2019 to June 2023

General objective of Project:

The Project has the following general objectives: (1) characterizing neurological and neurocognitive sequelae after SARS-CoV-2 infection of different severities over time; (2) evaluating the trajectory of neurocognitive test scores after SARS-CoV-2 infection; and (3) evaluating viral shedding and differences in cellular and humoral immune response after SARS-CoV-2 infection in relation with reported neurological and neurocognitive symptoms and neurocognitive test score.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 68: Markers of triclabendazole resistant fasciolasis the highlands of Perú
Funded with U.S. Federal Funds, under subcontract signed between Universidad de
Texas Medical Branch – Galveston and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 58,028 | 217,237 |
| Training | 0 | 0 |
| Travel | 2,120 | 8,106 |
| Consulting | 16,500 | 59,967 |
| Equipment and/or supplies | 7,652 | 28,783 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 2,606 | 9,689 |
| Total direct costs | 86,906 | 323,782 |
| Indirect costs | 8,484 | 32,147 |
| Total indirect costs incurred | 95,390 | 355,929 |

Researcher: José Eduardo Gotuzzo Herencia

Project performance Term: August 2019 to July 2024

General objective of Project:

The Research Projects has the following general objectives: (1) Detect candidate genetic markers associated with Triclabendazole Resistance (TCBZ-R) in Peru; (2) Validate the genetic markers associated with TCBZ-R using independent cohorts and determine if the genetic basis of resistance is conserved between populations of parasites that infect animals and humans; and (3) Define the transcriptional alterations associated with TCBZ-R in Peru.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 69: One-health approach to study human Fasciola hepatic transmission and inform strategic control
 Funded with U.S. Federal Funds, under subcontract signed between Universidad de Texas Medical Branch - Galveston and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 180,768 | 678,993 |
| Training | 306 | 1,180 |
| Travel | 6,139 | 23,111 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 36,411 | 136,631 |
| Lab and patient care services | 1,071 | 3,970 |
| Contractual expenses | 0 | 0 |
| Others | 10,625 | 39,900 |
| Total direct costs | 235,320 | 883,785 |
| Indirect costs | 14,558 | 54,324 |
| Total indirect costs incurred | 249,878 | 938,109 |

Researcher: Martin Montes Delgado

Project performance Term: April 2022 to March 2027

General objective of Project:

Determining the critical steps in the transmission of F. hepatic infection to humans by analyzing environmental, temporal-spatial data, and the distribution of the infection in the different hosts using a one-health approach. Demonstrate the accuracy and efficiency of tests to assess Fasciola hepatica infection in multiple hosts and environmental samples including recombinant polymerase amplification tests and serological tests such as urine Fasciola hepatica Fas2 Antigen capture ELISA.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 70: Prevention Through Vaccination Training (Prevent) Program
 Funded with U.S. Federal Funds, under subcontract signed between Universidad de
 Vanderbilt and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 26,504 | 99,073 |
| Training | 19,240 | 73,366 |
| Travel | 3,977 | 14,934 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 3,594 | 13,487 |
| Total direct costs | 53,315 | 200,860 |
| Indirect costs | 1,591 | 6,143 |
| Total indirect costs incurred | 54,906 | 207,003 |

Researcher: Theresa Jean Ochoa Woodell

Project performance Term: May 2023 to December 2027

General objective of Project:

This is an institutional development project to strengthen the capacity of the Instituto de Medicina Tropical Alexander von Humboldt - IMTAvH and the Universidad Peruana Cayetano Heredia - UPCH, via the Peru-Vanderbilt Prevention through Vaccination Training Program (PREVENT). The overall objective of PREVENT is to develop a cadre of Researchers and educators equipped with modern knowledge and experience to lead research and training in vaccine-preventable diseases in Peru and to encourage Researchers based in the United States of America to participate in research on vaccination in low and middle income countries.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 71: Impacto de El niño sobre el mercurio ambiental and exposición humana
 Funded with U.S. Federal Funds, under subcontract signed between University at
 Albany - State University of New York and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 6,766 | 25,475 |
| Training | 0 | 0 |
| Travel | 33 | 125 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 8,394 | 31,470 |
| Total direct costs | 15,193 | 57,070 |
| Indirect costs | 1,946 | 7,107 |
| Total indirect costs incurred | 17,139 | 64,177 |

Researcher: Juan Jaime Miranda Montero

Project performance Term: June 2019 to June 2023

General objective of Project:

Testing the main hypothesis that El Niño is associated with higher methylmercury - MeHg exposure in nearby ASM communities.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 72: Administración de medicamentos en masa focal para la eliminación de la malaria Vivax (Flame)

Funded with U.S. Federal Funds, under subcontract signed between University At Albany - State University Of New York and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 100,620 | 375,535 |
| Training | 0 | 0 |
| Travel | 6,392 | 23,906 |
| Consulting | 71,945 | 270,225 |
| Equipment and/or supplies | 48,597 | 179,650 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 39,545 | 149,096 |
| Total direct costs | 267,099 | 998,412 |
| Indirect costs | 13,568 | 50,300 |
| Total indirect costs incurred | 280,667 | 1,048,712 |

Researcher: Elmer Alejandro Llanos Cuentas

Project performance Term: August 2022 to May 2027

General objective of Project:

Determining the effectiveness of Focal mass drug administration - FMDA, to reduce the transmission of Plasmodium vivax parasite.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 73: An immune system for the city: a new paradigm for control of urban disease vectors

Funded with U.S. Federal Funds, under subcontract signed between University Of Pennsylvania and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 130,300 | 488,089 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 35,341 | 129,817 |
| Equipment and/or supplies | 11,912 | 45,353 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 41,942 | 157,245 |
| Total direct costs | 219,495 | 820,504 |
| Indirect costs | 12,946 | 48,285 |
| Total indirect costs incurred | 232,441 | 868,789 |

Researcher: Valerie Andrea Paz Soldan Parlette
Project performance Term: July 2019 to June 2024

General objective of Project:

Developing a new paradigm for the control of dangerous insects following the model of the adaptive immune system. The project will adapt aspects of the immune system from the scale of cells to that of landscapes and will test the new approach against a conventional one using a randomized cluster design in an ongoing Chagas disease vector control program in the city from Arequipa, Peru.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 74: Spatially responsive mass vaccination strategies for urban rabies
Funded with U.S. Federal Funds, under subcontract signed between University Of
Pennsylvania and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 156,594 | 585,842 |
| Training | 0 | 0 |
| Travel | 5,210 | 19,576 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 1,685 | 6,309 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 19,468 | 73,221 |
| Total direct costs | 182,957 | 684,948 |
| Indirect costs | 11,200 | 42,403 |
| Total indirect costs incurred | 194,157 | 727,351 |

Researcher: Valerie Andrea Paz Soldan Parlette

Project performance Term: April 2022 to March 2024

General objective of Project:

This proposal aims to produce an urgently needed novel approach for the control of urban rabies and other vaccine-preventable diseases through vaccination strategies incorporating spatial optimization and queuing theory, with current practice.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 75: Syphilis immunology and biology to improve clinical management and vaccine design

Funded with U.S. Federal Funds, under subcontract signed between University of Southern California and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 58,377 | 218,408 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 3,111 | 11,630 |
| Lab and patient care services | 636 | 2,412 |
| Contractual expenses | 3,750 | 14,325 |
| Others | 1,148 | 4,358 |
| Total direct costs | 67,022 | 251,133 |
| Indirect costs | 8,534 | 32,244 |
| Total indirect costs incurred | 75,556 | 283,377 |

Researcher: Carlos Fernando Cáceres Palacios

Project performance Term: February 2021 to August 2023

General objective of Project:

The study is based on enrolling people with syphilis infection and following them to see how their laboratory values and clinical development change after receiving treatment.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 76: Clinical trial comparing the effectiveness of cefixime versus penicillin G for treatment of early SY

Funded with U.S. Federal Funds, under subcontract signed between University of Southern California and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 49,130 | 183,814 |
| Training | 0 | 0 |
| Travel | 360 | 1,293 |
| Consulting | 6,168 | 23,342 |
| Equipment and/or supplies | 17,846 | 66,186 |
| Lab and patient care services | 10,000 | 36,410 |
| Contractual expenses | 0 | 0 |
| Others | 5,302 | 19,495 |
| Total direct costs | 88,806 | 330,540 |
| Indirect costs | 7,942 | 29,949 |
| Total indirect costs incurred | 96,748 | 360,489 |

Researcher: Carlos Fernando Cáceres Palacios

Project performance Term: July 2021 to June 2025

General objective of Project:

Evaluating the efficacy of Cefixime in the treatment of early Syphilis in comparison with penicillin G Benzathine and determine the predictors of treatment failure among the participants.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 77: Deep VZN - Discovery & Exploration of emerging pathogens – viral zoonosis
Funded with U.S. Federal Funds, under subcontract signed between University of Southern California and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 2,097 | 7,881 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 42 | 153 |
| Total direct costs | 2,139 | 8,034 |
| Indirect costs | 5,639 | 20,972 |
| Total indirect costs incurred | 7,778 | 29,006 |

Researcher: Patricia Jannet García Funegra

Project performance Term: March 2022 to December 2022

General objective of Project:

Documenting clinical outcomes and risk factors for mild, moderate, and severe disease in people with SARS-CoV-2 infection or influenza. Also, define the magnitude, quality, and longevity of immune responses to SARS-CoV-2 or influenza infection. And to characterize the levels and duration of viral excretion in people infected with SARS-CoV-2 or influenza. Characterize phenotypic and genotypic changes in SARS-CoV-2 and influenza viruses during the course of infection using next-generation sequencing.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 78: Evaluating susceptibility of treponema pallidum to Novel antibiotics in clinical samples

Funded with U.S. Federal Funds, under subcontract signed between University of Southern California and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 3,433 | 13,023 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 1,694 | 6,295 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 570 | 2,156 |
| Total direct costs | 5,697 | 21,474 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 5,697 | 21,474 |

Researcher: Carlos Fernando Cáceres Palacios

Project performance Term: November 2022 to October 2024

General objective of Project:

In this Project, they will build on the successful clinical and epidemiological studies of syphilis infection to conduct a randomized, non-comparative pilot trial among patients with early syphilis infection. The proposed pilot Project is designed to explore whether treatment with linezolid (600 mg orally, twice daily, for 5 days or 600 mg orally, twice daily, for 10 days) compared to penicillin G benzathine (2.4 million units, intramuscularly) in patients with and without human immunodeficiency virus-HIV infection. This is a two (2) year pilot study, which will enroll sixty (60) participants with early syphilis infection from a clinical site in Peru.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 79: Enhancing global health security
Funded with U.S. Federal Funds, under subcontract signed between University of
Washington and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 385,482 | 1,444,186 |
| Training | 362 | 1,343 |
| Travel | 22,818 | 85,271 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 145 | 538 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 5,563 | 20,721 |
| Total direct costs | 414,370 | 1,552,059 |
| Indirect costs | 25,156 | 92,201 |
| Total indirect costs incurred | 439,526 | 1,644,260 |

Researcher: César Paul Eugenio Carcamo Cavagnaro

Project performance Term: January 2022 to September 2024

General objective of Project:

Conducting a situational analysis to review surveillance systems in association with the technical working group.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 80: D43 Chronic Non-communicable CVDS and comorbidities in Perú
Funded with U.S. Federal Funds, under subcontract signed between University of
Washington and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 45,440 | 169,264 |
| Training | 39,030 | 146,926 |
| Travel | 774 | 2,859 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 1,983 | 7,423 |
| Total direct costs | 87,227 | 326,472 |
| Indirect costs | 5,331 | 19,871 |
| Total indirect costs incurred | 92,558 | 346,343 |

Researcher: Stella Maria Hartinger Peña

Project performance Term: March 2022 to March 2026

General objective of Project:

Developing the research careers of fellows in the area of cardiovascular disease, implementation science and environmental exposure; provide intensive training opportunities and build capacity in a range of scientific disciplines and relevant skills to achieve research independence. The long-term goal of this program is to build a sustainable and collaborative research training infrastructure to develop Peruvian Researcher scientists capable of designing and implementing interventions that address unmet health needs, including translation of evidence-based interventions and implementation and dissemination of effective policies to improve public health in Peru.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 81: Ictus: Interdisciplinary cerebrovascular diseases training program in South America

Funded with U.S. Federal Funds, under subcontract signed between University of Washinton and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 17,350 | 64,799 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 17,662 | 67,874 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 3,154 | 12,049 |
| Total direct costs | 38,166 | 144,722 |
| Indirect costs | 2,119 | 7,959 |
| Total indirect costs incurred | 40,285 | 152,681 |

Researcher: Héctor Hugo García Lescano

Project performance Term: June 2014 a May 2025

General objective of Project:

Continuing building a cadre of Peruvian doctors to reduce mortality and morbidity from cerebrovascular disease in Peru. Improve research in the management of cerebrovascular disease and post-cerebrovascular patient rehabilitation in Peru through workshops, didactic courses and training at the master's level in research methodology with precepts for young Peruvian doctors. Support clinical research projects with mentors in Peru for all mid- and long-term physicians-in-training to obtain data for thesis papers, publications, and future grant applications in the fields of cerebrovas Peruvian/Brazilian Amazon center of excellence and post-stroke rehabilitation. Improving the quality of stroke care and post-stroke rehabilitation in Peru through implementation science.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 82: Population assessment of Alzheimer's and related dementias in rural northern Perú

Funded with U.S. Federal Funds, under subcontract signed between University of Washinton and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 35,827 | 134,185 |
| Training | 0 | 0 |
| Travel | 1,274 | 4,699 |
| Consulting | 2,000 | 7,366 |
| Equipment and/or supplies | 6,350 | 23,927 |
| Lab and patient care services | 30,550 | 112,781 |
| Contractual expenses | 0 | 0 |
| Others | 64,051 | 237,047 |
| Total direct costs | 140,052 | 520,005 |
| Indirect costs | 577 | 2,140 |
| Total indirect costs incurred | 140,629 | 522,145 |

Researcher: Héctor Hugo García Lescano

Project performance Term: August 2019 a May 2024

General objective of Project:

Population-based studies of cognitive impairment and dementia in rural communities by establishing a baseline of cognitive status.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 83: CCASANET 2021-2026, Caribbean, Central and South America Network
Funded with U.S. Federal Funds, under subcontract signed between Vanderbilt
University Medical Center and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 45,207 | 169,046 |
| Training | 0 | 0 |
| Travel | 7,060 | 26,846 |
| Consulting | 24,175 | 89,321 |
| Equipment and/or supplies | 19,174 | 71,221 |
| Lab and patient care services | 14,245 | 53,900 |
| Contractual expenses | 0 | 0 |
| Others | 4,958 | 18,544 |
| Total direct costs | 114,819 | 428,878 |
| Indirect costs | 7,206 | 27,157 |
| Total indirect costs incurred | 122,025 | 456,035 |

Researcher: José Eduardo Gotuzzo Herencia

Project performance Term: May 2022 to April 2026

General objective of Project:

CCASANET: Caribbean, Central and South American Network for the Epidemiology of Human Immunodeficiency Virus - HIV. This Project creates and maintains a shared repository of HIV data from the Caribbean and Central and South America, and uses the combined data to answer questions about the characteristics of the regional HIV epidemic.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 84: CCASANET 2020-2022, Caribbean, Central and South America Network
Funded with U.S. Federal Funds, under subcontract signed between Vanderbilt
University Medical Center and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 0 | 0 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 0 | 0 |
| Indirect costs | 2,808 | 10,298 |
| Total indirect costs incurred | 2,808 | 10,298 |

Researcher: José Eduardo Gotuzzo Herencia

Project performance Term: February 2020 to January 2023

General objective of Project:

Caribbean, Central and South American Network for the Epidemiology of Human Immunodeficiency Virus - HIV. This Project creates and maintains a shared repository of HIV data from the Caribbean and Central and South America, and uses the combined data to answer questions about the characteristics of the regional HIV epidemic.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 85: Statistical methods for correlated outcome and covariate errors in studies of HIV/AIDS

Funded with U.S. Federal Funds, under subcontract signed between Vanderbilt University Medical Center and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 10,957 | 41,351 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | 10,957 | 41,351 |
| Indirect costs | 522 | 1,994 |
| Total indirect costs incurred | 11,479 | 43,345 |

Researcher: Larissa Otero Vegas

Project performance Term: February 2019 to January 2024

General objective of Project:

Planning the development of a pragmatic clinical trial to evaluate the optimal duration of Tuberculosis treatment in patients co-infected with HIV, as well as a reminder pill box, to increase adherence to treatment.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 86: Nih-Receptores Huerfanos
Funded with U.S. Federal Funds, under subcontract signed between Yale University
and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 13,597 | 50,131 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 2,776 | 10,680 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 935 | 3,468 |
| Total direct costs | 17,308 | 64,279 |
| Indirect costs | 1,567 | 5,798 |
| Total indirect costs incurred | 18,875 | 70,077 |

Researcher: Abraham Jaime Vaisberg Wolach

Project performance Term: April 2019 to May 2023

General objective of Project:

The general objective of this proposal is to identify the molecular pathways of neuronal function, which are new targets for intervention through the isolation of at least two new neuroactive compounds from plants used in Peruvian traditional medicine for the treatment of mental disorders. This will be achieved through the implementation of a research platform for the study of new pharmacological targets for mental disorders based in our institution. The aforementioned platform is derived from previous pilot work and brainstorming sessions with our network of local and US collaborators.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 87: Transmission dynamics of residual malaria in the amazon: defining a
roadmap to malaria elimination
Funded with U.S. Federal Funds, under subcontract signed between Yale University
and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 71,770 | 269,521 |
| Training | 0 | 0 |
| Travel | 10,892 | 40,912 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 19,678 | 74,814 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 13,518 | 50,670 |
| Total direct costs | 115,858 | 435,917 |
| Indirect costs | 9,112 | 33,428 |
| Total indirect costs incurred | 124,970 | 469,345 |

Researcher: Dionicia Baziliza Gamboa Vilela
Project performance Term: April 2019 to March 2024

General objective of Project:

The main objective is to identify the risk factors for infection and residual disease of Malaria, both at the individual and family level. It will provide samples of parasites for detailed molecular analyzes of the population and epidemiological data to develop new mathematical models of malaria transmission.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 88: Immunology of asymptomatic malaria and the effects of immunity on plasmodium transmission
Funded with U.S. Federal Funds, under subcontract signed between Yale University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 41,272 | 155,147 |
| Training | 0 | 0 |
| Travel | 2,630 | 9,930 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 267 | 992 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 424 | 1,570 |
| Total direct costs | 44,593 | 167,639 |
| Indirect costs | 2,824 | 10,439 |
| Total indirect costs incurred | 47,417 | 178,078 |

Researcher: Katherine Jessica Torres Fajardo
Project performance Term: April 2019 to March 2024

General objective of Project:

The main objective is to compare the inflammatory response and response capacity of innate immune cells of clinically ill and asymptomatic patients with malaria. The defined biomarkers are validated, and we question whether asymptomatic patients are prone to developing diseases in recurrent infections. The results of these experiments are to identify innate immune biomarkers as well as B and T cell responses that predict disease outcome and mosquito transmission.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 89: Spatiotemporal adaptation of anopheles darling in diverse ecological settings

Funded with U.S. Federal Funds, under subcontract signed between Yale University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 30,395 | 113,817 |
| Training | 0 | 0 |
| Travel | 6,131 | 22,980 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 3,761 | 14,497 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 3,261 | 12,285 |
| Total direct costs | 43,548 | 163,579 |
| Indirect costs | 2,469 | 9,125 |
| Total indirect costs incurred | 46,017 | 172,704 |

Researcher: Dionicia Baziliza Gamboa Vilela

Project performance Term: April 2019 to March 2024

General objective of Project:

This Project will address three under-studied facets that will provide key details of how this vector maintains its dominant role in Amazon malaria transmission dynamics by: 1) outlining the importance of anthropogenic breeding sites leading to a high productivity and dispersal of mosquitoes near human habitation; 2) to examine the rapid adaptation in modified landscapes of location (indoor/outdoor) and nocturnal timing of biting behavior; and 3) show how the preferences/changes of this mosquito species interact with Plasmodium asymptomatic people. vivax to maintain hypoendemic transmission.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 90: Translational research development for endemic infectious diseases of Amazonia

Funded with U.S. Federal Funds, under subcontract signed between Yale University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 0 | 0 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 0 | 0 |
| Total direct costs | <hr/> 0 | <hr/> 0 |
| Indirect costs | 16 | 61 |
| Total indirect costs incurred | <hr/> 16 | <hr/> 61 |

Researcher: Dionicia Baziliza Gamboa Vilela

Project performance Term: November 2018 to February 2023

General objective of Project:

The objective of this new training program in research in infectious diseases of the Project, with a focus on the training of candidates from Iquitos (National University of the Peruvian Amazon). This research training program is explicitly focused on increasing and maintaining research capacity in emerging and endemic infectious diseases primarily in Peru, particularly those found in the Peruvian Amazon. This training program will focus especially on infectious diseases associated with significant morbidity and mortality in the Peruvian Amazon.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 91: El comportamiento alimentario con azúcares del vector de la Malaria
Nyssorhynchus Darlingi y el desarrollo de cebos de azúcares tóxicos atractivos y
eficaces (ATSB) para aumentar el éxito de la intervención en el Perú
Funded with U.S. Federal Funds, under subcontract signed between Yale University
and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 533 | 2,007 |
| Training | 0 | 0 |
| Travel | 1,058 | 3,986 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 273 | 1,018 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 2,076 | 7,743 |
| Total direct costs | 3,940 | 14,754 |
| Indirect costs | 4,110 | 15,459 |
| Total indirect costs incurred | 8,050 | 30,213 |

Researcher: Dionicia Baziliza Gamboa Vilela

Project performance Term: April 2019 to March 2023

General objective of Project:

The objective of this project is to provide innovative quantitative information on the timing, location and frequency of sugar feeding essential for male mosquito reproductive success and for maximizing female egg production and survival in the main South American malaria vector, nyssorhynchus darling. Our studies in the field and in a biosphere in the Peruvian Amazon will allow us to develop, for the first time in a tropical forest environment, an attractive toxic bait to augment local malaria interventions that can lead to eradication in similar environments worldwide.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 92: La infección por plasmodium disminuye los títulos de anticuerpos de COVID -19 preexistentes y compromete la inmunidad en comunidades con alto riesgo de Malaria en la Amazonía Peruana

Funded with U.S. Federal Funds, under subcontract signed between Yale University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 2,820 | 10,729 |
| Training | 0 | 0 |
| Travel | 2,625 | 10,112 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 3,003 | 11,327 |
| Lab and patient care services | 67 | 256 |
| Contractual expenses | 0 | 0 |
| Others | 6,494 | 24,634 |
| Total direct costs | 15,009 | 57,058 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 15,009 | 57,058 |

Researcher: Katherine Jessica Torres Fajardo

Project performance Term: July 2021 to March 2023

General objective of Project:

Analyzing whether malaria can compromise the natural response of pre-existing antibodies against SARS-CoV-2, in order to improve the management of COVID-19 in communities in the Peruvian Amazon. We hypothesize that acute malaria and asymptomatic malaria accelerate the loss of pre-existing natural IgG antibodies against SARS-CoV-2 in people living in the Peruvian Amazon; For this reason, this study will aim to determine the dynamics of specific IgG antibody levels against SARS-CoV-2 proteins (Receptor-binding domain, the stabilized protein S ectodomain, S2 ectodomain and nucleocapsid of SARS-CoV-2) and Plasmodium (PvMSP8 and PvMSP10) during malaria infection in people from communities at high risk of malaria in the Peruvian Amazon. In addition, the B cell response to SARS-CoV-2 and Plasmodium infection one month after malaria infection will be determined.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 93: Core B Data Management
Funded with U.S. Federal Funds, under subcontract signed between Yale University
and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|---------------------------|-------------------------|
| <u>Direct costs</u> | | |
| Employee benefits | 13,568 | 50,778 |
| Training | 289 | 1,081 |
| Travel | 2,945 | 11,089 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 2,422 | 9,180 |
| Lab and patient care services | 0 | 0 |
| Contractual expenses | 0 | 0 |
| Others | 1,654 | 6,216 |
| Total direct costs | 20,878 | 78,344 |
| Indirect costs | 1,058 | 3,911 |
| Total indirect costs incurred | 21,936 | 82,255 |

Researcher: Dionicia Baziliza Gamboa Vilela

Project performance Term: April 2019 to March 2024

General objective of Project:

The objective of this project is to support study design, development/validation of case report forms, data cleaning, and analysis.

Universidad Peruana Cayetano Heredia

Individual statement of expenses

Project 94: Ampliando la caja de herramientas para la prevención de sarcopenia y osteoporosis en peruanos que envejecen con VIH: Un estudio de validación
Funded with U.S. Federal Funds, under subcontract signed between Yale University and Universidad Peruana Cayetano Heredia

Statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

| Expenses | Amount in US\$ | Amount in S/ |
|--------------------------------------|-------------------|-----------------|
| <u>Direct costs</u> | | |
| Employee benefits | 0 | 0 |
| Training | 0 | 0 |
| Travel | 0 | 0 |
| Consulting | 0 | 0 |
| Equipment and/or supplies | 0 | 0 |
| Lab and patient care services | 4,531 | 16,800 |
| Contractual expenses | 0 | 0 |
| Others | 2,996 | 10,935 |
| Total direct costs | 7,527 | 27,735 |
| Indirect costs | 0 | 0 |
| Total indirect costs incurred | 7,527 | 27,735 |

Researcher: Patricia Jannet García Funegra
Project performance Term: April 2022 to June 2027

General objective of Project:

Exploring the validity of three brief screening tools for sarcopenia and osteoporosis that have been used in primary care settings in Others countries for the general population and to collect preliminary patient-centered data regarding aging-related expectations, level of disability, and stigma associated with Human Immunodeficiency Virus - HIV, using validated tools that can help inform future work in this area.

Universidad Peruana Cayetano Heredia

Notes to the consolidated statement of expenses

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

1. Background of the University that manages the Projects

Universidad Peruana Cayetano Heredia (hereinafter the University) is a Peruvian NGO that designs and implements innovative research and projects that enhance the capabilities and improve access to opportunities for vulnerable people, contributing to the achievement of a more inclusive society and sustainable development. The University began its work in 1986, by the will of a group of multidisciplinary professionals, motivated to reverse the high rates of chronic child malnutrition in Peru and the risk factors associated with it. More than 30 years of experience and innovations, with an integral perspective of development, have expanded the field of intervention of the University to eight lines of action and have driven the way to internationalization to Latin America and Africa. It works in alliance with the central government, regional and local governments, international cooperation, academic institutions, civil society, organized community and private enterprise that contributes value.

2. Material accounting policies

The material accounting policies applied for the preparation of the consolidated statement of expenses for the period from January 1, 2023 to December 31, 2023 are as follows:

- (a) The Consolidated statement of expenses of the Projects was prepared by the University on a cash receipts and disbursements basis of accounting; under this basis, contractual expenses are recognized on the date of payment.
- (b) The indirect costs budget is derived from the estimated amounts agreed between the cooperating entities and the University.
- (c) The University accounts for its transactions in soles and for the conversion of projects to U.S. dollars it uses the exchange rate prevailing at the date of recording of the expense.

3. Costs incurred

The costs incurred in the Projects have been executed in accordance with the approved budgets for the twelve (12) month period from January 1, 2023 to December 31, 2023, with total costs incurred of US\$10,593,906.

Notes to the consolidated statement of expenses (continued)

3.1 Employee benefits

The following is a breakdown of contractual expenses comprising employee benefits:

| | US\$ | S/ |
|--|-----------|------------|
| Salaries | 2,050,441 | 7,698,492 |
| Bonuses | 1,532,550 | 5,759,335 |
| Statutory bonuses | 594,577 | 2,198,866 |
| Contributions to EsSalud | 317,231 | 1,191,469 |
| employee severance indemnities - CTS | 280,021 | 1,037,195 |
| Vacations | 99,815 | 374,763 |
| Healthcare service providers - EPS | 23,635 | 88,389 |
| Life insurance called Seguro d Vida Ley 4916 | 8,812 | 33,073 |
| Grants to interns | 8,569 | 31,983 |
| Family allowance | 6,035 | 22,943 |
| Risky work insurance - SCTR | 5,967 | 22,260 |
| Contractual expenses | 1,689 | 6,327 |
| Indemnities | 1,578 | 5,753 |
| Prior year contractual expenses | 972 | 3,525 |
| Vouchers, gif cards, consumer cards | 668 | 2,500 |
| Transportation at request | 429 | 1,630 |
| Total | 4,932,989 | 18,478,503 |

3.2 Equipment and/or supplies

A breakdown of contractual expenses in Equipment and/or supplies is shown below:

| | US\$ | S/ |
|--|-----------|-----------|
| Laboratory Supplies & Accessories | 367,588 | 1,376,462 |
| Chemical Inputs and Reagents | 309,922 | 1,160,393 |
| Major Assets for Research Projects | 302,537 | 1,138,976 |
| Labware & Accessories | 69,707 | 267,012 |
| Minor Assets for Research Projects | 59,418 | 221,442 |
| Animals and veterinary supplies | 39,095 | 147,888 |
| Stationery, office supplies | 18,792 | 70,231 |
| Medications, drugs, and substances | 17,185 | 62,968 |
| Hardware, paint, and plumbing materials | 11,876 | 44,788 |
| Cleaning and Cleaning Materials | 10,818 | 40,717 |
| Computer supplies and accessories | 9,862 | 37,248 |
| Office Supplies | 6,744 | 25,399 |
| Printing supplies and advertising material | 3,515 | 13,134 |
| Vestimentas, implementos y uniformes | 348 | 1,280 |
| Total | 1,227,407 | 4,607,938 |

Independent auditor's report on the evaluation of the internal control system of the Projects

To the members of the Board of Universidad Peruana Cayetano Heredia

1. We have audited the accompanying consolidated statement of expenses of the ninety-four (94) Research Projects (hereinafter the Projects) implemented by Universidad Peruana Cayetano Heredia (a nonprofit educational institution), funded with U.S. Federal Funds, under funding contracts and subcontracts signed by Universidad Peruana Cayetano Heredia with the following funding institutions: (i) National Institute of Health - NIH; (ii) Centro de Control de Enfermedades - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella, (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program; and (v) several U.S. universities, for the period of twelve (12) months from January 1, 2023 to December 31, 2023; and we have issued an unqualified audit opinion on such consolidated statement of expenses dated August 29, 2024.
2. We performed our audit of the consolidated statement of expenses of the ninety-four (94) Research Projects in accordance with the Generally Accepted Government Auditing Standard. In planning and performing our audit of the consolidated statement of expenses the ninety-four (94) Research Projects, we considered the internal control system in place at the University over financial reporting (internal control) as a basis to design our audit procedures for the purpose of expressing an opinion on the Consolidated statement of expenses but not to express an opinion on the effectiveness of the University's internal control; accordingly, we expressed no such opinion.
3. The Board of Universidad Peruana Cayetano Heredia is responsible for establishing and maintaining an internal control structure to manage the Projects. In fulfilling this responsibility, estimates and judgments by the Board are required to assess the expected benefits and related costs of internal control structure policies and procedures. The objectives of an internal control structure are to provide management with reasonable, but not absolute, assurance that the assets are safeguarded against loss from unauthorized use or disposition; transactions are executed in accordance with Board's authorization and in accordance with the terms of the contracts and subcontracts signed and transactions are recorded properly to permit the preparation of the Projects' consolidated statement of expenses, in accordance with the basis of accounting described note 2 (a) to the consolidated statement of expenses. A deficiency in internal control exists when the design or operation of a control does not enable Management or its personnel in the ordinary course of their assigned functions to prevent or detect misstatement on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement in the consolidated statement of expenses of will not be prevented or detected on a timely basis. Our consideration of the internal control structure was limited to the purpose

Independent auditor's report on the evaluation of the internal control system of the Projects (continued)

described in the first paragraph and was not intended to identify deficiencies in internal control that may be considered significant deficiencies or material weaknesses. We did not identify any deficiencies in internal control that we considered to be a material weakness as defined above.

Countersigned by:

Luis Acosta Peche & Asociados S. Civil de R. L.

Luis R. Acosta Peche

(Partner)

Peruvian Certified Public Accountant

Registration No 14042

Lima, Peru

August 29, 2024

Universidad Peruana Cayetano Heredia

Independent auditor's report on ninety-four (94) Research Projects funded with U.S. Federal Funds under contracts and subcontracts signed between Universidad Peruana Cayetano Heredia with the following funding institutions: (i) National Institute of Health - NIH; (ii) Center of Disease Control - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program, and (v) several U.S. universities

Additional notes to the evaluation of the internal control system of the Projects

For the period of twelve (12) months from January 1, 2023 to December 31, 2023

We evaluated the evidence related to the effectiveness in the design and operation of the internal control system implemented in the Research Projects funded by the Federal Funds of the United States of America, under the funding contracts and subcontracts signed between Universidad Peruana Cayetano Heredia and the following funding institutions: (i) National Institute of Health - NIH; (ii) Center for Disease Control - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella; (iv) PEPFAR: U. S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program; and (v) several U. S. universities; for which, we established the conditions of the internal control system and its operation during the twelve (12) months from January 1, 2023 to December 31, 2023.

The evaluation of the internal control system in place at the Projects' executing unit for the year under audit has been conducted in order to show that the criteria defined by the Internal Control - Integrated Framework - COSO are followed and/or complied with in an adequate and timely manner in terms of:

- i. Control environment.
- ii. Risk assessment.
- iii. Management control activities.
- iv. Accounting and financial reporting system.
- v. Monitoring activities.

Our work involved the evaluation of:

(a) Organizational structure

- Projects have an installed capacity that basically comprises human and material resources and an information system, for which it has an organizational structure designed and structured in accordance with the activities it carries out, whose functions are duly delimited in the Organization and Functions Manual. We have verified that there is an adequate segregation of duties and that Projects personnel are qualified to perform the positions they occupy and that they are aware of the

Additional notes to the evaluation of the internal control system of the Projects (continued)

institutional objectives and goals (control environment)).

- Project-implementing institutions have established appropriate policies and procedures to minimize risks related to the effectiveness and efficiency of operations, the preparation and presentation of financial information, and compliance with laws and regulations (risk assessment and risk management).
- Management control activities include the protection and safeguarding of assets, as well as access to computerized systems and data archiving maintained in the ERP Oracle Research Projects module (management control activity).

- (b) Evaluations and review of expenditures (procurement of goods, services and Contractual expenses of personnel))

We reviewed and evaluated the internal control of Universidad Peruana Cayetano Heredia, relating to the execution of the Contractual expenses for Research Projects, to obtain a sufficient understanding of the design of control policies and procedures, and whether those policies and procedures have been implemented.

Procurement of goods and services

The procurement and contracting processes for goods and services were examined within the framework of the funding contracts and subcontracts signed, which are called by the Logistics Area and controlled by the Accounting and Treasury Area. The purpose of this examination was to verify that the supporting documentation is duly supported by reliable vouchers and kept with the Institution's files, that they are duly authorized and correspond to Contractual expenses eligible under the contracts and are correctly accounted for.

Contractual expenses

We verified contractual expenses derived from the hiring of personnel in total or partial service of the Project, including salaries, social security, bonuses, vacations, compensation for time of services and other labor benefits in accordance with Peruvian legislation in force.

We verified that the hiring of personnel complied with national regulations and in accordance with the employment contracts duly certified by the Ministry of Labor and Employment Promotion in Peru, which specify; duties, hiring modality, professional category and salary.

We verified that workers' salary payments are made on a monthly basis for each Research Projects, delivering their respective payment slips required by labor legislation, complying with the payment of bonuses, compensation for time of service, vacations, Essalud contributions, among others. The imputation of the worker's salary varies according to whether he/she is an administrative or a researcher, since the administrative workers receive a fixed salary and the Researchers receive a fixed part and a variable part corresponding to the Research Projects in which he/she participates.

Additional notes to the evaluation of the internal control system of the Projects (continued)

We verified that social benefits payments were made: bonuses, compensation for time of service and vacations, on the corresponding dates and in the corresponding periods.

Withholdings for pension plans, insurance and taxes are made according to a detailed calculation and are paid to the entities that collect them (Pension Fund Administrators - AFPs and the National Superintendency of Customs and Tax Administration - SUNAT) within the deadlines established by the Peruvian labor legislation in force.

Universidad Peruana Cayetano Heredia keeps orderly files containing: personnel contracts, duly signed pay slips, with proof of payment of social benefits, proof of tax withholdings, social security fund payments, tax payments, payroll and social security payments.

We verified that the personnel files contain: staff hiring application, staff contract, contract checklist, single staff record, police record certificate, domiciliary certificate, copy of ID or foreigner's card, resume, copy of degrees and.

We verified that the personnel contracts, duly signed, are digitalized and archived in a folder synchronized to the cloud of the Universidad Peruana Cayetano Heredia.

We verified that the Contractual expenses of Travel are supported with settlements of accommodation, mobility and travel carried out only for personnel with an employment relationship with a list of supporting documents and their invoices, receipts and sworn statements.

(c) Results of the evaluation of the internal control system of the Projects as part of the Audit

Based on the results of the evaluation carried out on the use of the funds received for the implementation of the ninety-four (94) Research Projects financed by federal funds from the United States of America, through the financing contracts and subcontracts signed between the Universidad Peruana Cayetano Heredia with the following funding institutions: (i) National Institute of Health - NIH; (ii) Center for Disease Control - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella, (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program and (v) several universities in the United States of America, for the period of twelve (12) months from January 1, 2023 to December 31, 2023, we have not found any situations that merit being mentioned as part of this report.

Report on evaluation of the University's compliance with the terms of the funding contract and subcontracts and applicable laws and regulations

To the members of the Board of Universidad Peruana Cayetano Heredia

1. We have audited the accompanying consolidated statement of expenses of the ninety-four (94) Research Projects (hereinafter the Projects) implemented by Universidad Peruana Cayetano Heredia (a nonprofit educational institution), funded with U.S. Federal Funds, under funding contracts and subcontracts signed by Universidad Peruana Cayetano Heredia with the following funding institutions: (i) National Institute of Health - NIH; (ii) Centro de Control de Enfermedades - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella, (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program; and (v) several U.S. universities, for the period of twelve (12) months from January 1, 2023 to December 31, 2023; and we have issued an unqualified audit opinion on such consolidated statement of expenses dated August 29, 2024.
2. Except for not having a peer review quality control program, as stated in our report on the Consolidated fund accountability statement, we performed our audit in accordance with Government Auditing Standards (GAS) issued by the Comptroller General of the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated statement of expenses is free from material misstatements arising from significant deviations from the terms of the contracts and subcontracts, and applicable laws and regulations that may have a direct and material impact on the amounts reported in the consolidated statement of expenses.
3. Universidad Peruana Cayetano Heredia, as an implementing unit, has complied with the terms of the funding subcontracts and laws and regulations applicable to the ninety-four (94) Research Projects funded with U.S. Federal Funds, under funding contracts and subcontracts signed by Universidad Peruana Cayetano Heredia with the following funding institutions: (i) National Institute of Health - NIH; (ii) Centro de Control de Enfermedades - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella, (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program; and (v) several U.S. universities. In obtaining reasonable assurance about whether the consolidated statement of expenses is free of material misstatements, we performed tests on the University's compliance with the terms of the subcontracts, and applicable laws and regulations. However, our purpose was not to express an opinion on the general overall compliance with those terms. Accordingly, we express no such opinion. We also performed compliance test on the Projects' contracts and subcontracts with certain laws and regulations applicable to counterparty contributions. The results of our tests of compliance did not disclose any instance of noncompliance that should be reported under U.S. Government Auditing Standards.

Report on evaluation of the University's compliance with the terms of the funding contract and subcontracts and applicable laws and regulations (continued)

Countersigned by:

Luis Acosta Peche & Asociados S. Civil de R. L

Luis R. Acosta Peche

(Partner)

Peruvian Certified Public Accountant

Registration No 14042

Lima, Peru

August 29, 2024

Universidad Peruana Cayetano Heredia

Independent auditor' report on the ninety-four (94) Research Projects funded with U.S. Federal Funds under contracts and subcontracts signed between Universidad Peruana Cayetano Heredia and the following funding institutions: (i) National Institute of Health – NIH; (ii) Centro de Control de Enfermedades - CDC; (iii) Navsup Fleet Logistics Support Center Sigonella, (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program, and (v) several U.S. universities

Additional notes to the report on compliance with the terms of financing contracts and subcontracts, applicable laws and regulations

For the twelve (12) months from January 1, 2023 to December 31, 2023

In conducting an evaluation of compliance with the terms of applicable contracts, subcontracts, laws and regulations, we plan to execute audit procedures, which provide reasonable assurance of detecting cases of intentional or unintentional non-compliance with the terms of the contracts and subcontracts, regulations and applicable laws that could have a significant effect on the consolidated statement of expenses. Such procedures were determined in our opinion and on a sample basis and were as follows:

- We identified contractual clauses, which, in our opinion, were not complied with, may have a direct and significant effect on the consolidated statement of expenses.
- We assessed the inherent risk and control over the occurrence of a significant breach of contract.
- We verified whether payments have been made in accordance with the terms of applicable contracts, subcontracts, laws and regulations.
- We determined on a sample whether the funds have been spent for unauthorized purposes or are not in accordance with the applicable terms of the subcontracts.
- We verified whether the Contractual expenses incurred by the Research Projects have been authorized and/or endorsed by the Principal Researcher, properly presenting the documentation that supports them.
- We verified that the internal controls applied by the Universidad Peruana Cayetano Heredia for the acquisition of goods and services have been complied with in accordance with the levels of approval and minimum required number of quotes.
- We validated that there are contracts for the acquisition of a good or service, that the established deadlines are met and that there is a conformity of the service or receipt of the good.
- We verified the existence of original payment receipts (invoices, receipts, tickets, others).
- We verified if the submissions to be rendered by the Research Projects have been authorized and/or endorsed by the Principal Researcher, duly presenting the documentation that supports them.
- We validated that the deadlines established in the subcontract have been met, for the presentation of the operational reports to the funding Institution.

Additional notes to the report on compliance with the terms of financing contracts and subcontracts, applicable laws and regulations (continued)

- We verified compliance with the submission of operational and financial reports to the financing entities through the FFR - Federal Financial Reporting format, through the PMS system.
- We verified that the calculation of the Overhead (indirect cost), is in accordance with the guidelines established in the financing contracts and subcontracts, has been transferred to the indirect cost centers and used for the purposes established according to the directives of the Universidad Peruana Cayetano Heredia.
- We verified compliance with the regulations in the classification of assets to Contractual expenses Mayres at US\$5,000; Others Contractual expenses are considered as supplies.
- We reviewed the procedure for opening Projects and that the start dates match the financing contracts and subcontracts.
- We reviewed contracts, subcontracts and addenda to determine the closing date of each of the Research Projects.

Based on our evaluation on the use of the funds received for the execution of the ninety-four (94) Research Projects financed by federal funds of the United States of America, through the financing contracts and subcontracts signed between the Universidad Peruana Cayetano Heredia and the following funding institutions: (i) National Institute of Health - NIH; (ii) Center for Disease Control – CDC; (iii) Navsup Fleet Logistics Support Center Sigonella, (iv) PEPFAR: U.S. President's Emergency Plan for AIDS Relief endorsed by the Department of Defense HIV/AIDS Prevention Program and (v) several universities in the United States of America, for the period of twelve (12) months from January 1, 2023 to December 31, 2023, we have not evidenced situations that may need to be included in this report.

Opportunities for improvements and recommendations

During the course of our audit of the consolidated statement of expenses for the period from January 1, 2023 to December 31, 2023, we have evidenced the following situations that deserve to be disclosed and are the following:

1. Dates stated in contracts and/or sub-contracts of Projects other than the dates reported in the statements of expenses

Observation:

As a result of the review of the information reported in the consolidated statement of expenses, we have shown that the completion dates of certain Projects are not the same as those stated in the addenda. This situation is due to the fact that the General Administration of Projects has not implemented a directive referring to the timely updating of the data in the computer system for each Project, caused by the modifications (extensions, reductions, scope, etc.) to the contracts via addenda.

It should be noted that to date the Administrators of the identified Projects proceeded to update the date in the ERP ORACLE-PM.

The cases identified are presented below:

| Project Number | Date of Project termination | |
|----------------|-----------------------------|-------------|
| | Per Oracle | Per addenda |
| Project 94 | 30/06/2024 | 30/06/2027 |
| Project 79 | 30/06/2024 | 29/09/2024 |
| Project 60 | 3/06/2024 | 31/05/2024 |
| Project 23 | 30/06/2023 | 14/06/2023 |
| Project 61 | 14/06/2026 | 15/04/2026 |
| Project 84 | 30/04/2023 | 31/01/2023 |
| Project 46 | 1/03/2023 | 31/12/2027 |
| Project 35 | 4/11/2018 | 28/02/2023 |
| Project 18 | 31/05/2026 | 31/05/2028 |

Recommendation:

Set a formal directive describing the timing and procedure to update the information on the Projects database to ensure reports with accurate and updated information are available.

Opportunities for improvements and recommendations (continued)

Comments of Universidad Peruana Cayetano Heredia:

The General Administration of the Universidad Peruana Cayetano Heredia, updated the dates and has developed a diagrammed office PPT slide presentation, which specifies the opening and modification of data in the ORACLE ERP, with the update of all information related to the opening, and modification of data in research projects. The procedure described is in the process of approval and dissemination to administrators. The Administration estimates that it will enter the Testing Phase before the end of 2024. Although this is a procedural and non-material observation, it is being implemented as described.

2. Some Projects have not been assigned with specific project managers

Observation:

During the course of our audit, certain delay has occurred in the delivery of accounting information by the University, mainly due to the fact that some Research Projects did not have an Administrator exclusively designated to take care of a given project, or otherwise, designate the Researcher to take charge of managing duties.

Major cases identified:

| Project Number | Budget executed | |
|---|-----------------|---------|
| | US\$ | S/ |
| Project 86 Nih-Receptores Huérfanos | 18,875 | 70,077 |
| Project 56 Multidisciplinary Training Program on Neuropsychiatry and behavioral disorders in First Nations (NEUFIN) | 80,127 | 299,805 |
| Project 2 Program for advanced research capacities for AIDS in Perú (Paracas) harnessing implementation science | 229,604 | 857,444 |
| Project 57 Isolation and identification of CXCR4 and CXCR7 agonists from traditional phytopharmaceuticals as potential novel drugs for mental disorders | 41,897 | 157,692 |

Recommendation:

In order to achieve the integrity of the objectives set by each Research Project, we recommend assigning to the Projects a responsible and suitable person, who manages all administrative activities (planning, organization, direction and control) and that the Researchers dedicate themselves to activities related to their work in the Project. The responsible persons may be in charge of several research projects, depending on their size, complexity and location.

Comments of Universidad Peruana Cayetano Heredia:

Currently, all projects are assigned a responsible administrator. However, in four specific cases, the administration is still managed by the researchers. This year, we have started a systematic process to gradually transfer the administration of the funds from the researchers to specialized administrators. Part of this process includes the percentage allocation of the time commitment, thus ensuring a reasonable and technically defined workload. In addition, we are implementing controls so that all new projects include in their budget the allocation

Opportunities for improvements and recommendations (continued)

of an administrator. This process is ongoing and is expected to be completed by the end of the year.

3. Difference arising between the data shown in the Project Management Modules and Accounting Module

Observation:

As of October 1, 2023, the University acquired a new Oracle Cloud ERP, composed of different modules and within which there is GL (General Ledger) and Project Management (PM - Project Management), both modules process the information with the following parameters:

| PM (Project module) | GS (accounting module) |
|--------------------------------------|------------------------|
| | |
| Number of Project | Number of Project |
| Budget item | ----- |
| Kind of expense (accounting account) | Accounting account |
| Currency S/ and US\$ | ----- |
| ----- | Currency S/ |

As shown in the table above, the main differences between the two modules are: the budget item and types of currencies; consequently, the General Administration must carry out a reconciliation between both modules for the issuance of the statement of expenses reports of each Project, which are presented to the cooperating entities as well as to the external reviewers (audit) in US dollars and differentiated by affected budget item. In this regard, the process of said reconciliation to be carried out has not been formally established as a methodology for the preparation and presentation of the statements of expenditures on each reporting date.

Recommendation:

Set a guideline, a methodology for the reconciliation of information from the accounting management and project management modules, in the preparation and presentation of the expenditure statements of the Projects.

Comments of Universidad Peruana Cayetano Heredia:

We consider this observation to be procedural and not material in nature.

Opportunities for improvements and recommendations (continued)

Follow-up on prior year audit recommendations

Below are recommendations for improvement issues from previous years and their current status:

| Observation | Action taken by the University | Current status |
|--|---|----------------|
| 2016 | | |
| 1. Cost of personnel in Research Projects | The University, in coordination with the Department of Systems and Computer Science, has developed a module for assigning tasks, approving the activities carried out and respective control; this module is internally developed under the formats established by the National Institute of Health (NIH); This module will enter test mode in a white march plan, starting in September 2024, with the intention of identifying faults to be corrected in a timely manner. | In progress. |